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1 Introduction 
1.1 Biology of Adeno-Associated Virus 
Adeno-associated virus (AAV) is a nonpathogenic member of the Parvoviridae 
family which’s members are characterized as small and non-enveloped. The 
AAV capsid has an icosahedral symmetry of approximately 20 to 30 nm 
diameter and contains a linear single-stranded DNA genome around 4.8 kb. In 
the 1960s, AAV was found and defined as a contaminant of purified adenovirus 
(Atchison et al. 1965; Hoggan et al. 1966) and now AAV has been widely 
concerned and used in recent decades. AAV is a dependovirus and there are 
two proposed names for this species: Adeno-associated dependoparvovirus A 
(primate dependoparvovirus, including most of AAV serotypes) and 
Adeno-associated dependoparvovirus B (serotype AAV5 only).  
Different AAV serotypes are isolated from different species. There are 12 
human AAV serotypes and more than 120 serotypes of non-human primates 
have been investigated so far. Most of AAV serotypes can infect diverse tissues 
but with significant divergence of transduction efficiency, showing different 
organizational affinity (Figure 1) (Chiorini et al. 1997; Chiorini et al. 1999; Gao 
et al. 2002; Gao et al. 2004; Mori et al. 2004; Muramatsu et al. 1996; Rutledge 
et al. 1998; Samulski et al. 1982; Schmidt et al. 2008; Srivastava et al. 1983; 
Xiao et al. 1999).  
Although most people are infected with AAV it is considered non-pathogenic 
(Mingozzi and High 2013). On the contrary, AAV infection has been proposed to 
be benefit to people in some cases. AAV2 infection causes apoptosis of human 
cervical cancer cells (Alam and Meyers 2009), as well as the apoptosis in 
multiple breast cancer cells but has no effect on normal cells (Alam et al. 2011). 
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Furthermore, because of the low immunogenicity and site-specific integration, 
AAV is considered as a highly promising and prevalent gene therapy vector.  
 
Figure 1 The divergence of susceptibility with AAV serotypes in different tissues. These 
serotypes differ in their tropism, or the types of cells they infect, making AAV a very useful 
system for preferentially transducing specific cell types. The chart gives a summary of the 
tropism of AAV serotypes, indicating the optimal serotype(s) for transduction of a given organ. 
CNS= central nervous system (adapted from Asokan et al. 2012) 
In the very beginning AAV was recognized as a defective virus because it would 
not infect cells successfully unless a helper virus exist, e.g. adenovirus (Ad), 
herpes simplex virus type 1 and 2 (HSV1, HSV2), human cytomegalovirus 
(HCMV) or human papillomavirus (HPV) were present (Atchison et al. 1965; 
Buller et al. 1981; Georg-Fries et al. 1984; McPherson et al. 1985; Ogston et al. 
2000; Walz et al. 1998).  
Helper functions are performed from E1a, E1b, E2a, E4 and VA RNA in 
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adenovirus (Muzyczka 1992), or ICP0, ICP4, as well as UL5, UL8, UL52 and 
UL29 in herpes virus (Weindler and Heilbronn 1991). In addition, DNA damage 
caused by UV radiation, gamma irradiation or chemical treatment results in 
AAV activation. The helper virus co-infection could be performed before, after 
or simultaneously with AAV infection. When there is no helper virus, the viral 
DNA will be integrated into the host genome but will not undergo viral DNA 
replication or transcription. The AAV genome integrates into the specific 
position of the q-arm of chromosome 19 of the human genome (19q13.3-qter) 
(Cheung et al. 1980; Daya and Berns 2008; Kotin et al. 1990; Snyder et al. 
1993). When helper virus functions are present, AAV infectious proliferation will 
be performed when cells are stimulated by the external cofactors supported 
from helper virus  
1.1.1 Adeno-Associated Virus genome structure 
The adenovirus-associated virus type 2 (AAV2) genome is a single-stranded 
DNA (ssDNA) with 4781 bp nucleotides including inverted terminal repeats (ITR) 
and two ORFs. It is known that that both sense or antisense strand DNA can be 
packaged into AAV particle. The ITRs are cis-acting elements that regulate AAV 
replication, integration, rescue and packaging. The first 125 bases of the ITRs 
form a T-shaped hairpin structure with two small palindromes (B and C) and a 
larger configuration (A), and the residual 20 bases remain as unpaired 
D-sequences (Figure 2b). The ssDNA is flanked by ITRs and contains two open 
reading frames (ORFs): Rep and Cap. The left ORF Rep encodes 4 
non-structural proteins (Rep78, Rep68, Rep52 and Rep40) and their 
expression is controlled by the p5 and p19 promoters; the right ORF Cap 
encodes 3 capsid proteins (VP1, VP2, VP3) as well as the Assembly- Activating 
Protein (AAP) (Figure 2a).  
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Figure 2 Adeno-Associated Virus genome structure. (a) The 4.7 kb AAV2 genome contains 
Rep (white) and Cap genes (green) flanked by two ITRs (blue). Promoters p5 and p19 will 
guide two mRNAs transcription which are spliced differentially to produce 4 non- structural 
proteins (rep78, rep68, rep52, rep40). The capsid proteins (VP1, VP2, VP3) are initiated from 
the p40 promoter and are generated from two mRNAs via alternative splicing and start codon 
usage. The blue bar represents AAP which is translated from the second ORF of cap gene. (b) 
ITR structure. 125 bases of the ITRs form a T-shaped hairpin structure with two small 
palindromes (B and C) and a larger configuration (A), and the residual 20 bases remain as 
unpaired D-sequences. ORF= Open Reading Frame, ITRs= Inverted Terminal Repeat 
sequences, A=splice acceptor, D= splice donor. 
The p40 promoter regulates the Cap gene to transcribe 2.6kb and 2.3kb mRNA 
1 Introduction 
5 
 
and encode capsid proteins VP1, VP2 and of VP3 as well as AAP (Figure 2). 
The molecular weights of VP1, VP2, VP3 are 87kDa, 73kDa and 61kDa. The 
three VPs exist in the capsid at the molar ratio of 1:1:10, respectively. It is 
known that VP2 and VP3 can package progeny single-stranded DNA without 
VP1, but these progeny viruses are non-infectious, suggesting that VP1 is 
required for the infectivity. The unique fragment at the N terminus of VP1 was 
shown to comprise the phospholipase A2 (PLA2) activity and particularly the 
change of residue 76HD/AN, severely impairs AAV infectivity (Girod et al. 2002). 
VP2 is a controversial component because it was indicated as an important 
capsid protein in the assembly of virus-like particles (Muralidhar et al. 1994). 
However, Warrington et al. showed VP2 to be unnecessary for the complete 
virus particle formation and an efficient infectivity and presented that VP2 can 
tolerate large insertions in its N-terminus, while VP1 cannot, probably because 
of the PLA2 domain (Warrington et al. 2004). Intact AAV particles can be 
formed with VP3 alone in the absence of helper functions and AAV genomes, 
provided that the VP3 is fused to a nuclear localization signal (Hoque et al. 
1999).  
1.1.2 Genetic engineering of the Adeno-Associated Virus 
Site-directed mutagenesis allows the deletion or insertion of a known target 
gene thus affecting the amino acid sequence and protein structure.  
Many studies have shown that peptides could be inserted into AAV capsids. 
AAV2 has a heparin-binding site around amino acid position 587 of capsid 
protein VP1 which can be substituted with other sequences. Consequently, the 
ability of this modified AAV to be neutralized with human serum is 
approximately 15-fold less reduced than AAV2 wild type (Huttner et al. 2003). 
Further studies also indicated some more specific sites could be used for 
insertion of heterologous sequences without influencing the assembly as well 
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as transduction activity. 
In recent years, the AAV mutants’ studies are more inclined towards the 
interaction between the amino acid on external surface and receptors. Zhong et 
al. established some modified AAV2 with tyrosine exchanging on the capsid 
surface (Y252F, Y272F, Y444F, Y500F, Y700F, Y704F, and Y730F) and 
detected increasing transduction efficiency because of the tyrosine-mutant 
AAV2 ubiquitination, which indicated that the main receptor binding site of AAV 
capsid is tyrosine (Zhong et al. 2008b). Moreover, they found epidermal growth 
factor receptor tyrosine kinase (EGFR-PTK) -mediated phosphorylation of 
tyrosine residues on AAV capsid protein is a prerequisite for ubiquitination of 
AAV2 capsids. The phosphorylated capsid could be ubiquitinated at the 
tyrosines and thus resulted in the reduced transduction efficiency, although the 
AAV entry has not been affected (Zhong et al. 2008a). 
Apart of the AAV Cap genetic modification, AAV genome DNA structure could 
also be modified. Typical AAV genome is a single-stranded DNA template 
flanked by ITR at both sides, and the events like DNA replication or 
transcription need the second-strand DNA synthesis. The second-strand 
synthesis is widely known as the rate-limiting step for AAV transduction, 
wherefore McCarty et al. constructed a new lab-made AAV genome DNA, 
which could form an intra-molecular double-stranded DNA template, named 
self-complementary AAV (scAAV), to avoid second-strand synthesis (McCarty 
et al. 2001) (Figure 3). During AAV infection process, the two complementary 
DNA fragments of AAV genome will form the double stranded DNA (dsDNA) 
after viral genome release from AAV particle and it leads to replication or 
transcription immediately. Subsequently, Buie et al. and Deepak et al. found the 
scAAV can greatly transduce and express genes in the liver or be used to treat 
hemophilia B (Buie et al. 2010; Raj et al. 2011).  
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Figure 3 Single-strand AAV (ssAAV) and self-complementary AAV (scAAV) 
conformations. Recombinant AAV genome, where the coding sequences are replaced by a 
transgene, which is flanked by the 3’ and 5’ ITR. (b) scAAV DNA synthesis process. The 
recombinant transgene in scAAV is expressed as an inverted repeat DNA sequence, as well 
as the deleted or mutated 3′ terminal repeats in the middle. This DNA is flanked by two 5′ 
terminal repeats at both sides. After AAV transduction, the inverted repeats perform the 
complementary pairing followed by the double-stranded DNA transcription, thereby bypassing 
the synthesis of the second strand DNA. Deletion or mutation of the 3’ terminal repeats 
prevents the function of Rep endonucleases to stabilize the self-complementary AAV genome 
dimeric formation. (adapted from Raj et al. 2011) 
1.1.3 Adeno-Associated Virus Trafficking 
The general process of AAV infection is carried out as follows. The external 
isolated AAV particles bind to the corresponding receptors or co-receptors on 
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the cell surface to perform the endocytosis. The low pH of the endosome leads 
to the exposure of the N-terminus of VP1 which is essential for endosomal 
escape and transportation into the nucleus. During AAV transportation, the 
capsid proteins are modified by phosphorylation and ubiquitination, followed by 
AAV degradation. However, the non-degraded viral particles enter the nucleus 
and are uncoated to release the AAV genome, which is converted to 
double-stranded (ds) DNA that is used for the expression of the encoded 
proteins through (Grieger and Samulski 2012; Nonnenmacher and Weber 2011; 
Qing et al. 1998; Seisenberger et al. 2001; Zhong et al. 2008b).  
AAV particle attachment on the cell surface could be mediated by specific 
glycans or glycoconjugates which thereby provide access to specific 
proteinaceous co-receptors binding (Huang et al. 2014). The main receptor is 
the heparan sulfate proteoglycan (HSPG) and co-receptors include: αVβ5, 
α5β1, hepatocyte growth factor receptor (c-MET), fibroblast growth factor 
receptor I (FGFR1), laminin receptor (LamR), CD9 tetraspanin family, 
platelet-derived growth factor receptor (PDGFR) and the epidermal growth 
factor receptor (EGFR) (Summerford and Samulski 1998; Summerford et al. 
1999; Asokan et al. 2006; Kashiwakura et al. 2005; Ling et al. 2010; Blackburn 
et al. 2006; Qing et al. 1999; Akache et al. 2006; Kurzeder et al. 2007; Di 
Pasquale et al. 2003; Weller et al. 2010). More recently, a genetic screen 
identified a previously uncharacterized transmembrane protein, KIAA0319L 
(denoted as AAV receptor, or AAVR) as being essential for endocytosis and 
Golgi trafficking of multiple AAV isolates (Pillay et al. 2016). Each of these 
receptors have been identified/verified using a facet of different methods 
highlighted in the follow table:  
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Table 1 AAV receptors and their validation (adapted from Pillay and Carette 2017) 
Receptor 
AAV 
serotype 
Validation 
siRNA 
knockdown 
Over-expression 
Ligand or 
ectodomain 
inhibition 
Binding 
Biodistribution/ 
infection 
correlation 
aVβ5 AAV2 - CS1 cell - 
Virus 
overlay 
assay 
- 
FGFR1 
AAV2, 
3H 
- Raji and KB cell both Dot blot - 
c-MET AAV2, 3 HuH7 cell NIH3T3 cell ligand 
Virus 
overlay 
assay 
- 
A5β1 AAV2 - 
CHOB2 and CS1 
cell 
ectodomain 
Solid phase 
binding 
profiles 
- 
CD9 AAV2 
MCF7 and 
T47D cell 
T47D, BT8Ca 
and BT12Ca cell 
- - 
HSPG-low vs 
HSPG-high cell 
Lam R 
AAV2, 3, 
8, 9 
NIH3T3 cell NIH3T3 cell 
Ligand for 
AAV8 
Yeast 
bait/prey 
assay 
 
PDGFR AAV5 NIH3T3 
HeLa and 32D 
cell 
both 
Co- 
precipitation 
Yes 
EGFR AAV6 
NIH3T3 and 
NH13 cell 
32D cell - 
Co- 
precipitation 
Yes 
AAVR 
AAV1, 2, 
3B, 5, 6, 
8, 9 
CRISPR/CAS9 
in HAP1, 
HeLa, 
HEK293, 
U2OS, A549, 
Huh7 cell 
NIH3T3, Rija, 
Caco-2 and HT29 
cell 
ectodomain ELISA, SPR - 
After AAV particles attachment, the intracellular molecule Dynamin, Rac1 or the 
phosphatidylinositol kinase PI3K mediate AAV2 particles internalization into the 
endosome by micropinocytosis, clathrin- independent carriers/GPI-enriched 
endocytic compartment pathway (CLIC/GEEC) (Nonnenmacher and Weber 
2011) or the clathrin-coated pathway (Bartlett et al. 2000; Weinberg et al. 2014).  
After AAV enters the cell, it was identified that AAV2 traffics via the late 
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endosomes (Ding et al. 2006) but this is possibly determined by the host cell. 
The comprehensive microtubule network is used for the transportation of AAV2 
particle which contained in the endosomal vesicles (Xiao and Samulski 2012) 
and localized near Golgi/ER transport proteins mediated by syntaxin-5 
(Johnson et al. 2011; Nonnenmacher et al. 2015).  
Virus degradation also occurs during the endocytic trafficking by multiple 
degradation pathways, such as ubiquitin-proteasome system, endo-lysosomal 
vesicles, ER-associated degradation (ERAD) and autophagy-based machinery. 
Previous research showed that the transduction of various AAV serotypes was 
enhanced after treatment with proteasome inhibitors MG132, bortezomib, 
N-acetyl-l-leucinyl-l-leucinyl-norleucinal (LLnL) or celastrol (Douar et al. 2001; 
Fisher et al. 1996; Madshus et al. 1984; Greber et al. 1997; Mizukami et al. 
1996). AAV2 virions are trafficked to the lysosome through early endosomes 
and late endosomes (Bartlett et al. 2000; Ding et al. 2006). There is no direct 
evidence that AAV transport is affected by ER, although ER-associated 
degradation was confirmed to be active as AAV transduction enhanced after 
endoplasmic reticulum-associated degradation inhibitors (Eer1) treatment 
(Berry and Asokan 2016). 
With the AAV entry non-degraded AAV particles gradually enter the cell nucleus 
via the Nuclear Pore Complex (NPC), followed by virus uncoating, releasing the 
ssDNA and utilizing free ITR 3' hydroxyl group as the primer to form the 
complementary DNA (Nonnenmacher and Weber 2012). In absence of the 
helper virus some AAV genomes could integrate in the host genome or remain 
as an episome in the nucleus to transcript and express proteins from the 
transgene cassette (Figure 4). In addition, if the helper function exists, more 
progeny virus will be assembled by the AAV packaging mechanism and be 
released from the cell. 
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Figure 4 Schematic representation of Adeno-Associated Virus life cycle. AAV2 binds 
onto the surface of a target cell via receptor and/or co-receptor facilitates the internalization of 
the virus. Before the endosomal escape, rAAV2 undergoes a conformational change where 
VP1 and VP2 are exposed because of endosomal acidification. AAV particles are delivered 
through the trans Golgi network to accumulate in the perinuclear. In the meantime, virus 
degradation occurs during the endocytic trafficking by different degradation pathways. AAV 
transfers through the nuclear pore complex (NPC) before uncoating, followed by ssDNA 
release, dsDNA synthesis, genome integration or remains episomally and facilitates mRNA 
transcription. (adapted from Daya and Berns 2008; Pillay and Carette 2017; Colella et al. 
2018) 
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1.1.4 Adeno-Associated Virus packaging mechanism 
The AAV assembly includes 2 steps. Firstly, VP protein assembly by AAP. AAP 
is crucial in targeting newly synthesized VP proteins to the nucleolus and 
promoting the assembly of the AAV capsid. The exact mechanism remains 
elusive, but it is thought to be a scaffold to concentrate the VP proteins in the 
nucleolus (Naumer et al. 2012). This step is rapid as accumulation of the viral 
capsid proteins and their assembly into empty particles occurs within the first 
20 min.  
The second step is genome packaging, which takes several hours. After the 
empty particle formation, the virus genome is melted into single-stranded DNA 
(ssDNA) with the help of Rep factors, and then the ssDNA enters the empty 
particle from the top of the five-fold axis of AAV capsid, with the DNA direction 
being 3’ to 5’ (DiPrimio et al. 2008; King et al. 2001) (Figure 5). Wu et al. found 
that the empty particle can only admit the ssDNA less than 5.2 kb, otherwise the 
external sequence at 5’ terminal of DNA could be digested by a nuclease (Wu et 
al. 2010). However, AAV 2, AAV5 and AAV8 were indicated the ability to deliver 
the genomes longer than 5.2 kb and expresses the proteins as long as the 
genome contains one ITR and the complete genome ORF. Finally, the complete 
virions are assembled and released from the cell (Geoffroy and Salvetti 2005). 
 
Figure 5 The Adeno-Associated Virus particle assembly process. Firstly, non- structural 
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proteins Reps are synthesized to regulate the AAV assembly process, followed by VP1, 2, 3 
capsid proteins expression from cap ORF as well as AAP encoding by a second ORF. The viral 
capsid proteins are accumulated and assembled by AAP rapidly. Secondly, the single-stranded 
DNA enters the empty particles from the five-fold axis of AAV capsid, and the direction of 
ssDNA entering is from 3’ to 5’. 
1.2 Biology of SUMOylation 
Small ubiquitin-related modifier (SUMO) was discovered as a reversible 
post-translational modification of proteins in the middle of 1990s. More than 
3,600 proteins can be SUMOylated at 7,300 SUMOylation sites so far. SUMO 
modification can regulate many substrate proteins in the life process, such as 
intracellular sub-localization, enzyme activity, protein structure and stability, 
and transcriptional activity (Herrmann et al. 2007). 
SUMO has only 18% sequence similarity to ubiquitin, but the structure after 
folding is highly similar that of ubiquitin (Bayer et al. 1998; Bernier-Villamor et al. 
2002; Mossessova and Lima 2000). Primates could express four SUMO family 
members: SUMO1, 2, 3, 4 (Guo et al. 2004; Melchior 2000). SUMO1, SUMO2 
and SUMO3 are ubiquitously expressed in all tissues, while SUMO4 is mainly 
expressed in organs such as kidney, lymph nodes or spleen. One study found 
that only SUMO2-deficient mice died of an earlier embryonic development due 
to severe developmental disorders, while SUMO1/SUMO3-deficient mice 
survived and multiplied, with no apparent abnormal phenotype (Evdokimov et 
al. 2008; Qi et al. 2014; Zhang et al. 2008). 
1.2.1 SUMOylation Catalytic Pathway 
SUMOylation is generally catalyzed by three enzymes (Kerscher et al. 2006), in 
which the E1 activation enzyme SAE1/SAE2 (also known as Aos1/Uba2) and 
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E2 binding enzyme UBC9 (Ubiquitin-Conjugating 9) are the only single 
enzymes, respectively. There are many kinds of E3 ligases participate in 
SUMOylation depending on different substrate modifications. The immature 
SUMO protein is modified by Sentrin-specific protease (SENP) to expose a 
stable di-glycine motif, followed by the activating E1 enzyme and conjugating 
E2 enzyme catalysis. E2 enzyme UBC9 plays a crucial role in the SUMO 
modification process. Apart from providing an activated SUMO protein, UBC9 
can directly conjugate SUMO to the specific substrate lysine residue (Flotho 
and Melchior 2013) (Figure 6). The substrate with one or more multiple 
residues could be SUMOylated by single SUMO protein or the SUMO protein 
chain. 
 
Figure 6 The SUMOylation pathway. During maturation process, 2~11 amino acids 
extensions of the immature SUMO protein at the C-terminus could be excised by SENP to 
expose the di-glycine motif Gly-Gly. The SUMO molecule is activated by a two-step hydrolysis 
of ATP, followed by SAE1/SAE2 complex conjugation via a thioester bond. SAE2 ship the 
SUMO to Ubc9 enzyme. Ubc9 recognizes the target protein which contains consensus 
sequence ΨKxD/E and catalyzes the formation of SUMO to the target protein, followed by the 
Ubc9 detachment. Different substrate proteins determine whether they need to utilize E3 
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enzyme or not. Ultimately, the target protein is SUMOylated. In addition, the SUMOylation 
process can be reversed by SENPs, which is named deSUMOylation. (adapted from Flotho 
and Melchior 2013). 
There are more than 600 known ubiquitin E3 ligases (Deshaies and Joazeiro 
2009) but only a handful of SUMO E3 ligase have been reported, such as the 
protein/inhibitor of the activated STAT proteins (PIAS family), the nuclear pore 
protein RanBP2, human cystathionine β-synthase (CBS), the polycomb group 
protein Pc2, tripartite motif-containing (TRIM) proteins and so on (Werner et al. 
2012; Yunus and Lima 2009; Kirsh et al. 2002; Pichler et al. 2002; Agrawal and 
Banerjee 2008; Kagey et al. 2003; Chu and Yang 2011; Meroni and Diez-Roux 
2005). Even though UBC9 can regulate SUMO conjugation to the target protein 
directly, it is still an indisputable fact that different E3 ligase can promote SUMO 
modification by different mechanisms. The E3 enzymes do not conjugate with 
SUMO molecules by covalent bond but with E2 (UBC9)/SUMO complex to 
promote the transfer of SUMO from E2 to the substrate.  
1.2.2 The SUMOylation consensus sequence 
Target proteins SUMOylation by mass spectrometry-based proteomics is 
complicated to be dealt with because of low modification stoichiometry and 
incompatibility with the classical database. The SUMO regulation is more 
complex than previously thought, due to the post-translational modifications of 
SUMO family members by phosphorylation, acetylation and ubiquitination. 
Most of the SUMOylated proteins have SUMO-interaction motifs (SIM) (Hecker 
et al. 2006) (Figure 7a) which are typically composed of multiple hydrophobic 
residues and an acidic residue (Song et al. 2004). SIM-containing proteins can 
be recruited to and immobilized on SUMOylated proteins, which may lead to 
their covalent SUMOylation owing to the proximity of SUMO ligases (Raman et 
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al. 2013; Silver et al. 2011) (Figure 7b, top), for example, SUMO group 
modification during the DNA damage response (DDR) in yeast was observed 
(Psakhye and Jentsch 2012). In the meanwhile, SIMs can facilitate the 
recruitment of UBC9 to the protein, resulting in covalent SUMOylation Lys 
residue (Figure 7b, bottom). 
 
Figure 7 SUMO-interaction motifs (SIMs) role in protein SUMOylation. (a) SUMO proteins 
are regulated by the SUMO-interaction motifs (SIMs) for their noncovalent interaction. (b) (b) 
The proteins contain SIM can be recruited to the SUMOylated proteins because of the 
proximity of SUMO ligases resulting in the covalent SUMOylation (top). In addition, SIMs 
improve the Ubc9 recruitment to the protein, leading the covalent SUMOylation of the 
surrounding lysine (K) residue (bottom). They both can regulate the target protein 
SUMOylation and keeping stability through SIM–SUMO interaction. (adapted from Hendriks 
and Vertegaal 2016) 
The scientists found the classical SUMOylation modification motif via many 
protein sequence analyses of nearby SUMO sites as Ψ-K-X-E/D. Ψ is a 
hydrophobic amino acid, and X is an arbitrary amino acid, X is any kind of 
amino acid and E/D are acidic amino acids. But more recently, the consensus 
sequence was updated. Adherence of SUMOylation to proteins containing the 
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basal KXE-type motif has been widely described, which is important for direct 
binding of the SUMO-conjugating enzyme UBC9 (Bernier-Villamor et al. 2002). 
KXE-type SUMOylation sites are detected easier across multiple screens 
(structure [IVL]K and KXE account for a very large proportion) (Matic et al. 2010; 
Yang et al. 2006). Intriguingly, the inverted sequence [ED]XK is also observed 
as a SUMOylation motif (Matic et al. 2010), which increases the range of the 
sequence that can be SUMOylated (Figure 8a). Since many sequences of the 
SUMOylated proteins have been confirmed, Hendriks et al. utilized IceLogo 
analysis to set up a strongest reference based on the currently know 
SUMOylation sequence in the SUMOylated proteins, which could help the new 
SUMOylation sites prediction in further studies (Figure 8b).  
 
Figure 8 SUMO consensus sequences a surrounding residue. (a) Hydrophobic (grey), 
negatively charged (red) and phosphorylation-dependent motifs (not shown) further optimize 
the basic motif. The inverted motif is most often observed separately from the forward motif, 
but it is not mutually exclusive with the forward motif. Square parentheses indicate that any 
one of the listed residues is present; blue shading indicates the SUMO-modified Lys residue. 
(b) Amino acids surrounding SUMOylation sites were compared with randomly occurring 
background frequencies of amino acids in all nucleus proteins. Amino acids displayed above 
the x-axis are enriched, whereas amino acids displayed below the x-axis are depleted around 
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SUMOylation sites. (adapted from Hendriks and Vertegaal 2016) 
1.2.3 SUMOylation in virus life cycles 
It has been discovered that many viral components can be SUMOylated and 
the viral infection is affected in host cells. Adenovirus core protein V contains 
SUMOylation consensus motifs that could affect adenoviral replication 
(Freudenberger et al. 2018), and the capsid protein VI regulates the antiviral 
response by modulation of the transcription factor Daxx during infection 
(Schreiner et al. 2013). Liu et al. found that the 3D polymerase, an 
RNA-dependent RNA polymerase (RdRp) of intestinal virus type 71 (EV71), 
undergoes both SUMO and ubiquitin modification during infection, which act to 
stabilize the polymerase and promote viral replication (Liu et al. 2016). The 
following influenza virus proteins like NS1, NP and M1 contain SUMO sites  
and the cellular PAF1 complex component parafibromin (CDC73) is also 
SUMOylated to affect influenza virus replication and assembly (Ngamurulert et 
al. 2009; Santos et al. 2013; Han et al. 2014; Wu et al. 2011; Domingues et al. 
2015). Numerous viral proteins have also been shown to interact with the 
SUMO conjugating enzyme (Ubc9) to be SUMOylated. The human 
papillomavirus (HPV) protein E2, which acts on viral replication and genome 
segregation and downregulates expression of the oncogenic E6 and E7, also 
interacts with Ubc9 (Wu et al. 2008). However, instead of using this interaction 
to affect the SUMOylation of other proteins, the viral E2 is itself SUMOylated.  
In addition, viral proteins or components can also inhibit SUMOylation of 
endogenous proteins in host cells during infection. For example, avian 
adenovirus CELO (chicken embryo lethal orphan) infection causes the 
inactivation of SUMO E1 enzyme by the Gam1 protein. Gam1 mediates E1 
enzyme (SAE1/SAE2) degradation by recruiting the cullin RING ubiquitin 
ligases and resulting in the degradation of SAE1 by the proteasome (Boggio et 
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al. 2004; Boggio et al. 2007). Adenovirus infection in HeLa cells could induces a 
reduction of SAE1 and SAE2.  
Moreover, some host factors have been confirmed to be SUMOylated to affect 
virus infection in the host cell. For example, the promyelocytic leukemia protein 
(PML), a prototypical TRIM protein also known as TRIM19, is involved in a 
chromosomal translocation associated with the clear majority of acute 
promyelocytic leukemia. PML, especially PML variant II, is the eponymous and 
main structural component of the PML nuclear bodies (PML-NBs) (Bernardi 
and Pandolfi 2007; Borden 2002; Geng et al. 2012). Experiments have shown 
that SUMOylated PML plays an important role in the formation of PML-NBs and 
require NBs-related protein Sp100, Daxx, HDAC1, CBP, p53 and Sp3 
recruitment. The death domain-associated protein (Daxx) and 
alpha-thalassemia retardation syndrome x-linked (ATRX) are the two 
components of PML oncogenic domain and are able to form a Daxx/ATRX 
complex by the activity of ATRX ATPase and Daxx’s histone deacetylases 
(Hollenbach et al. 2002). The Daxx/ATRX complex represents an intrinsic 
immune mechanism acting as viral defense against different viruses, such as 
herpes simplex virus 1 (HSV-1), human cytomegalovirus (HCMV), human 
epstein-barr virus (EBV), and kaposi's sarcoma-associated herpesvirus (KSHV) 
(Everett 2001; Preston et al. 1998; Tsukamoto et al. 2000; Everett et al. 2008; 
Everett and Murray 2005; Tsai et al. 2011; Kato-Noah et al. 2007; Lin et al. 1999; 
Wu et al. 2001). In return, other viruses have developed strategies to neutralize 
repression by Daxx/ATRX to overcome this barrier (Lukashchuk and Everett 
2010; Ullman and Hearing 2008). Since most of the components in NB are 
transcription factors, SUMOylation and interaction in NB will have a critical 
influence in regulating transcription. 
Altogether, post-translational modification by SUMOylation is a reversible 
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process and has various effects on target proteins interaction, localization, 
stability and activity. SUMOylation could regulate nuclear transport, DNA 
replication and repair as well as in mitosis and signal transduction (Herrmann et 
al. 2007). 
1.3 Previous work 
This thesis is based on a high throughput siRNA silencing screen performed to 
verify host cell factors that repress or enhance AAV2 transduction efficiency. 
This screen was performed by Prof. Jürgen Kleinschmidt, Dr. Florian Sonntag 
(DKFZ, Heidelberg, Germany) and Dr. Holger Erfle (ViroQuant core facility, 
Bioquant, Heidelberg, Germany) using two sub-genomic siRNA libraries 
(Extended Druggable Silencer siRNA Library and the Genome Extension 
Silencer Select siRNA Library) in HeLa cells. Statistical evaluation identified 
several proteins belonging to the SUMOylation pathway, with very high 
z-scores which led to follow up studies.  
Subsequently, siRNA knockdown of SUMO E1 enzyme Sae2 and SUMO E2 
enzyme Ubc9, which was performed by Dr. Christina Hölscher (DKFZ, 
Heidelberg, Germany) and Katharina Henrich (DKFZ, Heidelberg, Germany), 
showed an increased reporter AAV2 expression. Thus, confirming Sae2 and 
Ubc9 as host cell restriction factors. This work has been published in 2015 
(Figure 9) (Hölscher et al. 2015). 
1 Introduction 
21 
 
 
Figure 9 Two genome-wide siRNA libraries screen indicate that AAV transduction 
affected with SUMOylation pathway. (a) A total of 20,290 genes with their z-scores are 
shown in the distribution. The blue line above the dotted lines indicate 740 putative host cell 
restriction factors with z-score threshold of +1.7 (HRF; z-score > 1.7), and the red line below 
dotted lines shows 181 putative host cell dependency factors with z-score threshold of -1.7 
(HDF; z-score < -1.7). (b) SUMOylation pathway related protein ranking base on the z-scores. 
HDF=host cell dependency factors, HRF=host cell restriction factor. (adapted from Hölscher et 
al. 2015) 
1.4 Aim of study 
As a result of the siRNA screen and the previous work, Sae2 (SUMO E1 
enzyme) and Ubc9 (SUMO E2 enzyme) were confirmed as host cell restriction 
factors that affect AAV transduction. The objective of my PhD project is to 
identify and characterize the mechanism in which the SUMOylation pathway 
influences AAV transduction and challenge which step of AAV trafficking is 
affected by SUMOylation through the following ways: 
a. Confirmation of Sae2 and Ubc9 as host cell restriction factors for 
AAV transduction. 
b. Identification of the SUMO target within the AAV capsid. 
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c. Determination the impact of SUMOylation on AAV 
transduction/trafficking in the nucleus. 
d. Identification of additional host cell factors e.g. Daxx involved in the 
restriction of AAV either in concert or independent of SUMOylation. 
These studied should contribute to a broader understanding what exactly is 
SUMOylated to influence the AAV transduction and where the SUMOylation 
occurs. Furthermore, this study shall also give insight into some extra host cell 
factors that may be related to the SUMO pathway that affect AAV transduction. 
This serves to increase the comprehension of AAV and SUMOylation. 
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2 Materials 
2.1  Biological materials 
2.1.1 Eukaryotic Cells 
Designation Origin 
HeLa Human epithelial cervix adenocarcinoma cells containing the HPV 18 
genome. These cells were cultured in supplemented Dulbecco’s modified 
Eagle’s medium (DMEM) with 10% Fetal Bovine Serum (FBS), 1% 
L-Glutamin (L-Glu), 1% penicillin/streptomycin (P/S). 
A549 Adenocarcinomic human alveolar basal epithelial cells. These cells were 
cultured in supplemented with 10% FBS, 1% L-Glu, 1% P/S. 
HEK 293TT Human embryonic kidney cells expressing the simian virus T-antigen in 
two copies, respectively. These cells were cultured in DMEM containing 
62.5 μM Hygromycin B, 10% FBS, 1% L-Glu, 1% P/S 
HeLa-Gam1 HeLa modified cell which can overexpress adenoviral protein Gam1, the 
inhibitor of the SUMO pathway by interfering with the activity of E1 
enzyme after Doxycycline induction. These cells were cultured in DMEM 
containing, 10% FBS, 1% L-Glu, 62.5 μM Hygromycin B and Blasticidin. 
HeLa-Daxx KO HeLa with Death domain-associated protein (Daxx) knock out cell line 
which was produced with CRISPR/CAS9 system from Robin Njenga. 
These cells were cultured in DMEM containing 10% FBS, 1% L-Glu, 1% 
P/S. 
 
2.1.2 Prokaryotic Cells 
Strain Genotype 
E. coli MegaX DH10 
(Invitrogen) 
This strain provides the option of blue/white screening on plates 
containing either X-Gal or Bluo-Gal. 
F- mcrA ∆(mrr-hsdRMS-mcrBC) φ80lacZ ∆M15 ∆lacX74 recA1 
endA1 araD139 ∆(ara, leu)7697 galU galK λ - rpsL nupG tonA 
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E. coli XL-Blue 
supercompetant cells 
(Agilent Technologies) 
The XL1-Blue strain allows blue-white color screening. 
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´ proAB 
lacIqZ∆M15 Tn10 (Tetr)]. (Genes listed signify mutant alleles) 
2.1.3 Virus 
2.1.3.1 Adeno- associated virus 
Adeno-associated virus and Adeno-associated virus- mutants were produced 
by transfection of HEK293TT cells with the respective plasmids and purified by 
an Iodixanol gradient. 
Virus Type Reporter Virus Plasmid Source 
AAV2 AAV2 wt, Firefly #2772, #1814, #1995 This Thesis 
AAV2 AAV2 wt, ss Gaussia #2772, #1814, #3193 M. Müller 
AAV2 AAV2 wt, sc Gaussia #2772, #1814, #2485 M. Müller 
AAV2 AAV2 empty #2772, #1814 This Thesis 
AAV2 AAV2 K33R, Firefly #3588, #1814, #1995 This Thesis 
AAV2 AAV2 K39R, Firefly #3589, #1814, #1995 This Thesis 
AAV2 AAV2 K51R, Firefly #3590, #1814, #1995 This Thesis 
AAV2 AAV2 K61R, Firefly #3591, #1814, #1995 This Thesis 
AAV2 AAV2 K77R, Firefly #3592, #1814, #1995 This Thesis 
AAV2 AAV2 K92R, Firefly #3593, #1814, #1995 This Thesis 
AAV2 AAV2 K105R, Firefly #3594, #1814, #1995 This Thesis 
AAV2 AAV2 K137R, Firefly #3596, #1814, #1995 This Thesis 
AAV2 AAV2 K142+ 143R, Firefly #3597, #1814, #1995 This Thesis 
AAV2 AAV2 K161R, Firefly #3598, #1814, #1995 This Thesis 
AAV2 AAV2 K169R, Firefly #3599, #1814, #1995 This Thesis 
AAV2 AAV2 K527R, Firefly #3407, #1814, #1995 This Thesis 
AAV2 AAV2 K532R, Firefly #3419, #1814, #1995 This Thesis 
AAV2 AAV2 K549R, Firefly #3475, #1814, #1995 This Thesis 
AAV2 AAV2 VP1+VP3, Firefly #3523, #1814, #1995 This Thesis 
AAV2 AAV2 VP2+VP3, Firefly #3882, #1814, #1995 This Thesis 
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AAV2 AAV2 VP1/GFP-VP2/VP3, 
Firefly 
#3523, #3541, #1814, 
#1995 
This Thesis 
AAV2 AAV2 VP1/HA-VP2/VP3, 
Firefly 
#3523, #3542, #1814, 
#1995 
This Thesis 
2.1.3.2 Other Viruses 
Virus Type Reporter Virus Plasmid Source 
HPV58 HPV58 wt, Gaussia #1998 M. Müller 
IAV IAV wt, Gaussia unknown A. Marchini 
2.1.4 Media and Supplements 
2.1.4.1 Eukaryotic Cells 
Media and Supplements company 
Dulbecco´s Modified Eagle Medium (DMEM), 
low glucose 
Sigma-Aldrich 
Deisenhofen, Germany 
RPMI medium 1640 Sigma-Aldrich 
Deisenhofen, Germany 
Fetal Bovine Serum (FBS) PAN Biotec, 
Aidenbach, Germany 
L-glutamin (200mM) Genaxxon 
Ulm, Germany 
Penicillin/Streptomycin (10.000 units/ml Pen 
and 10.000μg/ml Strep) 
Gibco Life Technologies 
Paisley, UK 
HiPerFect transfection reagent Qiagen 
Hilden, Germany 
Polyethylenimine (PEI) Sigma-Aldrich 
Taufkirchen, Germany 
0.25% Trypsin-EDTA Gibco 
Eggenstein, Germany 
Hygromycin B (62.5 μM) Roche 
Mannheim, Germany 
Blasticidin Thermo Scientific 
Schwerte, Germany 
Doxycycline (50ng/ml) Sigma-Aldrich 
Taufkirchen, Germany 
Heparin Sigma-Aldrich 
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Taufkirchen, Germany 
Corresponding growth media for each cell line 
Designation Medium Supplements 
HeLa DMEM 
Low glucose 
1%Glu, 1%P/S 
A549 RPMI 
1640 
1%Glu, 1%P/S 
HEK 293TT DMEM 
Low glucose 
1%Glu, 1%P/S 
HeLa-Gam1 DMEM 
Low glucose 
1%Glu, 0.2mg/ml Hygromycin B, 
200ng/ml Blasticidin 
HeLa-Daxx KO DMEM 
Low glucose 
1%Glu, 1%P/S 
2.1.4.2 Prokaryotic Cells 
Media and Supplements Composition 
LB medium 100 g Tryptone 
50 g yeast extract 
100 g NaCl 
10L H2O, pH 7.5 
autoclaved 
LB agar plates 98.5% LB medium 
1.5% bacto-agar 
Autoclaved, respective antibiotics 
25ml/plate 
S. O. C medium Invitrogen 
California, USA 
Antibiotics stocks Ampicillin (Amp): 100mg/ml 
Kanamycin (Kan): 25mg/ml 
2.1.4.3 Long-term Storage  
Designation Composition 
Eukaryotic Cells 30%FBS 
2 Materials 
27 
 
10%DMSO 
60% non-supplement 
1ml/sample 
Prokaryotic Cells 0.3ml sterile glycerol (100%) 
1ml bacteria medium 
2.2 Molecular biology materials 
2.2.1 Plasmid 
All AAV2 capsid mutation plasmids were transformed in XL-blue chemically 
super competent cells after QuikchangeTM mutagenesis, and others are 
transformed in electrocompetent MxDH10 cells. 
Designation Plasmid Source 
#1814 pDGΔVP, AAV2/Ad-helper plasmid without cap-gene M. Müller 
#1995 pUF Luciferase (Luciferase reporter between AAV ITRs for 
production of selected clones carrying Luciferase reporter) 
M. Müller 
#2772 AAV2 wt capsid without ITRs (AG Grimm) for wt control 
multiwell peptide screening No Sfi site 
M. Müller 
#3193 AAV reporter, ss Gaussia M. Müller 
#2252 AAV reporter, sc Gaussia M. Müller 
#3588 mut K33R-AAV2 capsid, from #2772 This thesis 
#3589 mut K39R-AAV2 capsid, from #2772 This thesis 
#3590 mut K51R-AAV2 capsid, from #2772 This thesis 
#3591 mut K61R-AAV2 capsid, from #2772 This thesis 
#3592 mut K77R-AAV2 capsid, from #2772 This thesis 
#3593 mut K92R-AAV2 capsid, from #2772 This thesis 
#3594 mut K105R-AAV2 capsid, from #2772 This thesis 
#3596 mut K137R-AAV2 capsid, from #2772 This thesis 
#3597 mut K142+143R-AAV2 capsid, from #2772 This thesis 
#3598 mut K161R-AAV2 capsid, from #2772 This thesis 
#3599 mut K169R-AAV2 capsid, from #2772 This thesis 
#3407 mut K527R-AAV2 capsid, from #2772 This thesis 
#3419 mut K532R-AAV2 capsid, from #2772 This thesis 
#3475 mut K549R-AAV2 capsid, from #2772 This thesis 
#3512 N-eGFP Gateway pDEST vector This thesis 
#3513 N-HA Gateway pDEST vector This thesis 
#3523 VP1+VP3 (VP2 silence) on #2772 This thesis 
#3532 VP2+VP3 sequence in pENTR1A, SalI-NotI This thesis 
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#3541 eGFP-VP2+VP3 (gatewaw, #3532+#3512) This thesis 
#3542 HA-VP2+VP3 (gatewaw, #3532+#3513) This thesis 
#3882 VP2+VP3 (Quikchange, VP1 silence) on #2772 This thesis 
2.2.2 Oligonucleotides for mutagenesis or normal PCR 
All oligonucleotides were ordered and produced at MWG Eurofins in Ebersberg, 
Germany. 
Designation Sequence 5’ to 3’ 
AAV2 VP-K33R-F ACCACCACCAAGGCCCGCAGAGC 
AAV2 VP-K33R-R CGCTCTGCGGGCCTTGGTGGT 
AAV2 VP-K39R-F AGCGGCATAGGGACGACAGCAG 
AAV2 VP-K39R-R TGCTGTCGTCCCTATGCCGCTCT 
AAV2 VP-K51R-F TTCCTGGGTACAGGTACCTCGGAC 
AAV2 VP-K51R-R AGGGTCCGAGGTACCTGTACCCAG 
AAV2 VP-K61R-F TCAACGGACTCGACAGGGGAGAGC 
AAV2 VP-K61R-R GCTCTCCCCTGTCGAGTCCGTTGA 
AAV2 VP-K77R-F TCGAGCACGACAGAGCCTACGACC 
AAV2 VP-K77R-R CGGTCGTAGGCTCTGTCGTGCT 
AAV2 VP-K92R-F AACCCGTACCTCAGGTACAACCACG 
AAV2 VP-K92R-R GTGGTTGTACCTGAGGTACGGGT 
AAV2 VP-K105R-F AGGAGCGCCTTAGAGAAGATACGTCTT 
AAV2 VP-K105R-R AAAAGACGTATCTTCTCTAAGGCGCT 
AAV2 VP-K137R-F AGGAACCTGTTAGGACGGCTCC 
AAV2 VP-K137R-R CCCGGAGCCGTCCTAACAGGTT 
AAV2 VP-K142+143R-F ACGGCTCCGGGAAGAAGGAGGCCGGT 
AAV2 VP-K142+143R-R CTCTACCGGCCTCCTTCTTCCCGGAG 
AAV2 VP-K161R-F TCGGGAACCGGAAGGGCGGGCCA 
AAV2 VP-K161R-R TGCTGGCCCGCCCTTCCGGTTC 
AAV2 VP-K169R-F CAGCCTGCAAGAAGAAGATTGAATT 
AAV2 VP-K169R-R CAAAATTCAATCTTCTTCTTGCAG 
AAV2 VP-K527R-F GGCCCGGCCATGGCAAGCCACAGGGACGATGAAGA
AAAGTTT 
AAV2 VP-K527R-R AGGAAAAAACTTTTCTTCATCGTCCCTGTGGCTTGCC
ATGGCCG 
AAV2 VP-K532R-F CGATGAAGAAAGGTTTTTTCCTCAGAGC 
AAV2 VP-K532R-R TCTGAGGAAAAAACCTTTCTTCATCG 
AAV2 VP-K549R-F CAAGGCTCAGAGAGAACAAATGTGGACATTG 
AAV2 VP-K549R-R TTCAATGTCCACATTTGTTCTCTCTGAGCCTTG 
AAV2 VP1 silence-F ATTTAAATCAGGTGCGGCTGCCGATGGTTATCT 
AAV2 VP1 silence -R AACCATCGGCAGCCGCACCTGATTTAAATCATT 
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AAV2 VP2 silence -F AGGAACCTGTTAAGACCGCTC 
AAV2 VP2 silence -R TTTTCCCGGAGCGGTCTTAAC 
AAV2 VP2 only-F AAAGTCGACACGGCTCCGGGAAAAAAG 
AAV2 VP2 only-R AAAAGCGGCCGCTTACAGATTACGAGTCAGG 
2.2.3 oligonucleotides for siRNA knockdown 
Negative Control siRNA and all siRNAs targeting the SUMOylation pathway 
were purchased from Qiagen (Hamburg, Germany). 
Designation Sequence 5’ to 3’ Qiagen Number 
Negative control siRNA AATTCTCCGAACGTGTCACGT 1022076 
Hs_SAE2_3 (Sea2) CACCGGTTTCTCCCACATCGA SI04234433 
Hs_UBE2I_8 (Ubc9) ACCACCATTATTTCACCCGAA SI04185937 
2.2.4 Enzymes 
Designation Company 
Restriction enzymes New England Biolabs 
Frankfurt, Germany 
T4 DNA Ligase New England Biolabs 
Frankfurt, Germany 
KOD HiFi Polymerase Merck 
 Darmstadt, Germany  
Calf intestine alkaline phosphatase (CIP) New England Biolabs 
 Frankfurt, Germany 
RNAse Roche  
Mannheim, Germany 
Proteinase K Qiagen 
Hilden, Germany 
2.3 Virologic materials 
2.3.1 Solutions for AAV production 
Designation Composition 
AAV production Lysis Buffer 50 mM Tris, pH 8.5  
150 mM NaCl  
In H2O, pH 8.5 
 autoclave 
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PBS-MK 1 mM MgCl2  
2.5 mM KCl  
In PBS  
filter-sterilized 
PBS-MK/Nacl 1 M NaCl in PBS-MK 
 filter-sterilized 
Iodixanol (60%) Sigma-Aldrich  
Taufkirchen, Germany 
Phenol red Sigma-Aldrich  
Taufkirchen, Germany  
Benzonase (100.000 U/ml) Merck 
Darmstadt, Germany 
2.3.2 Sucrose gradient for AAV separation 
2.3.2.1 Iodixanol removal 
Designation Composition 
Zeba Spin Desalting Column, 7K 
MWCO (B2162579) 
Thermo Scientific 
 Schwerte, Germany 
2.3.2.2 Sucrose gradient 
Designation Composition 
10% Sucrose 10% sucrose in PBS-MK 
10 mM protease inhibitor cocktail 
filter-sterilized 
30% Sucrose 30% sucrose in PBS-MK 
10 mM protease inhibitor cocktail 
 filter-sterilized 
Phenol red 10ul in 1ml sample 
2.4 Buffers and Solutions for DNA extraction and analysis 
2.4.1 DNA plasmid extraction by phenol-chloroform 
Designation Composition 
Glucose mix 50mM glucose 
 10mM EDTA  
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25mM Tris HCl 
 in H2O, pH 8.0 
Alkali lysis buffer 200mM NaOH 1% SDS (w/v) 
 in H2O 
Sodium acetate 3M NaAc 
In H2O, pH 5.2 
Phenol mix Phenol-CIA mix 1:1 
100μg hydroxyquinoline per 100ml 
Chloroform-isoamyl alcohol 
mix (CIA) 
Chloroform-isoamyl alcohol mix 24:1 
TE buffer (1x) 10mM Tris 
1mM EDTA 
in H2O, pH 8.0 
2.4.2 Agarose gel electrophoresis  
Designation Composition 
1% agarose gel 0.33g agarose   
2ul ethidium bromide 
 In 33ml 1x TAE buffer 
Ethidium bromide Roth  
Karlsruhe, Germany 
TAE buffer (1x) 40mM Tris 
5.71% acetic acid (v/v)  
10% 500mM EDTA 
in H2O, pH 8.0 (v/v) 
6x loading buffer New England Biolabs, Frankfurt, 
Germany 
Quick-Load 100bp DNA ladder New England Biolabs, Frankfurt, 
Germany 
1 Kb Plus DNA Ladder Thermo Scientific 
 Schwerte, Germany 
2.5 Buffers and Solutions for protein analysis 
2.5.1 Protein concentration determination 
Designation Company 
Bradford reagent BioRad  
München, Germany 
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BSA standard (2 μg/μl) Thermo Scientific  
Waltham, USA 
2.5.2 Electrophoresis 
Designation Composition 
Tris buffer, pH 8.8 1M Tris 
In H2O, pH 6.8 
Tris buffer, pH 6.8 1 M Tris 
0.03% Bromphenol blue 
In H2O, pH 6.8 
3x protein loading buffer 30% glycerol 
6% SDS  
15% β-mercaptoethanol 
0.003% bromophenol blue 
187.5mM Tris in H2O, pH 6.8 
Ammonium Persulfate (APS) 10%APS (w/v) 
In H2O 
Acrylamide solution (30%AA) Roth,  
Karlsruhe, Germany 
TEMED Sigma-Aldrich,  
Deisenhofen Germany 
SDS 10% SDS (w/v) 
In H2O 
2.5.3 SDS-polyacrylamide gels 
Designation Composition 
12.5% separation gel (5 mini gel) 18.75ml 30% acrylamide solution 
 16.88ml 1M Tris/HCl buffer,   
8.48ml H2O pH 8.8 
450μl 10% SDS  
450μl 10% APS  
22.5μl TEMED 
2% stacking gel (5 mini gel) 1.5ml 30% acrylamide solution 
1.95ml 1M Tris/HCl buffer, pH 6.8 
11.25ml H2O 
150μl 10% SDS 
150μl 10% APS 
22.5μl TEMED 
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2.5.4 Western blot analysis 
Designation Composition 
TGS buffer (1x running buffer) 2.5mM Tris 
1.45% glycine 
0.1% SDS 
in H2O, pH 8.3 
EMBL buffer (1x transfer buffer) 2.5mM Tris 
1.45% glycine 
0.1% SDS 
in H2O, pH 8.3 
Blocking buffer 5% skim milk  
in PBS-T 
Washing buffer 0.3% Tween 20 (v/v)  
in 1x PBS 
Prestained protein ladder color plus NEB Biolabs 
Schwalbach, Germany 
Amersham Hybond membranes, PVDF GE Healthcare 
Buckinghamshire, UK 
Nitrocellulose membrane GE Healthcare 
Buckinghamshire, UK 
2.6 Immunological materials 
2.6.1 Antibody 
Designation Description Source 
A20 Raised against intact AAV2 particles J. Kleinschmidt 
B1 Raised against VP1, VP2 and VP3 of different AAV 
serotypes 
J. Kleinschmidt 
A69 Raised against the capsid proteins of VP1 and 
VP2 of different AAV serotypes 
J. Kleinschmidt 
A1 Raised against the capsid proteins of VP1 of 
different AAV serotypes 
J. Kleinschmidt 
Anti-SUMO1 raised against the amino acid sequence 1-101 of 
SUMO-1 from the human species (FL-101). 
Santa Cruz 
Anti-SUMO2/3 Polyclonal antibody recombinant protein encoding 
full length SUMO (PA5-11373). 
Thermo Scientific 
Anti-Daxx Monoclonal antibody corresponds to a region 
surrounding Gln255 of Daxx (25C12 Rabbit mAb). 
Cell Signaling 
Technology 
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Anti-HA probe Raised against a peptide mapping within an 
internal region of the influenza hemagglutinin 
protein (sc-805). 
Santa Cruz 
Anti-LamB1 raised against adherent spleen cells of human 
origin (H4A3, sc-20011) 
Santa Cruz 
Anti-Sae2 UBA2 Rabbit mAb recognizes endogenous level of 
total human UBA2 protein (D15C11) 
CST 
Anti-Ubc9 raised against the amino acid sequence 1-81 of 
UBC9 of human origin (C-12, sc-271057). 
Santa Cruz 
Anti-Myc Mouse monoclonal, raised against the amino acid 
sequence EQKLISEEDL of the human oncogene 
c-myc 
M. Müller 
Anti-Actin Mouse monoclonal antibody detecting human 
actin. The detected epitope lies between amino 
acid 18-40. 
MP Biomedicals 
 Solon, USA 
HPVK18L2 Mouse monoclonal antibody, detecting amino acid 
22-30 of HPV16 L2.  
M. Müller 
GAMPO HRP-coupled Goat-anti-mouse antibody Dianova 
GARPO HRP-coupled Goat-anti-Rabbit antibody Dianova 
AlexaFlour 488 AlexaFlour 488-coupled Goat-anti-mouse antibody Life Technologies 
AlexaFlour 594 AlexaFlour 594-coupled Goat-anti-Rabbit antibody Life Technologies 
AlexaFlour 594 AlexaFlour 594-coupled Donkey-anti-Goat 
antibody 
Life Technologies 
2.6.2 Immunoprecipitation 
2.6.2.1 Beads 
Designation Company 
SureBead Protein G Magnetic Beads (1ml) Bio-Rad 
Munich, Germany 
2.6.2.2 Buffer and solutions 
Designation Composition 
Non-denaturing lysis buffer 20 mM Tris-HCl, pH 8.0 
137 mM NaCl 
10% Glycerol 
1% NP40- freshly added 
2 mM EDTA 
In H2O 
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 1x protease inhibitor tablet (Roche) per 7 ml buffer freshly 
added 
NET-N buffer 20 mM Tris-HCl, pH 7.5 
100 mM NaCl 
1 mM EDTA 
1% NP-40 (freshly added) 
3x Loading buffer w/o 
β-mercapthoethanol 
30% glycerol 
 6% SDS 
 0.003% bromphenol blue 
 187.5mM Tris 
 in H2O, pH 6.8 
2.6.3 Immunofluorescence 
Designation Composition 
Fixation Solution 2% PFA  
in 1x PBS, pH 7.4 
Quenching Solution 50 mM Ammoniumchloride 
in 1x PBS 
Permeabilization Solution 0.2% Triton 100  
In 1x PBS 
Blocking solution 1% BSA  
in 1x PBS 
DAPI 100 mg/ml  
in 1X PBS 
Mounting medium Dianova 
Hamburg, Germany 
2.7 General buffer and solutions 
Designation Composition 
1x PBS 140 mM NaCl 
2.7 mM KCl 
8.1 mM Na2HPO4 
1.5 mM KH2PO4 
In H2O, pH 7.4, autoclave 
H2O Millipore, autoclave 
Methanol Sigma-Aldrich 
Deisenhofen, Germany 
Ethanol VWR 
Darmstadt, Germany 
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Isopropanol VWR 
Darmstadt, Germany 
Hydrochloric acid VWR 
Darmstadt, Germany 
Sodium hydroxide VWR 
Darmstadt, Germany 
2.8 Chemicals 
Designation Company 
Tryptone 
All chemicals were purchased from 
Sigma-Aldrich (Taufkirchen, Germany), 
AppliChem (Darmstadt, Germany), Merck 
(Darmstadt), Roth (Karlsruhe, Germany), Serva 
(Heidelberg, Germany), Fluka (Neu Ulm, 
Germany), Gerbu (Gaiberg, Germany), VWR 
(Darmstadt, Germany) and Life Technologies 
(Karlsruhe, Germany) 
Yeast extract 
NaCl 
Bacto-agar 
Ampicillin 
Kanamycin 
Zeocin (Zeo) 
Tris/Hcl 
MgCl2 
Kcl 
Glucose 
EDTA 
NaOH 
NaAc 
Hydroxyquinoline 
Ethidium bromide 
Acetic acid 
Bromphenol blue 
Ammonium Persulfate (APS) 
Acrylamide solut ion (30%AA) 
Glycine 
Skim milk 
Tween 20 
Protease inhibitor tablet 
PFA 
Ammonium Chloride 
Triton X 100 
BSA 
Na2HPO4 
KH2PO4 
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2.9 Kits 
Kits Company 
Beetle-Juice BIG KIT PJK 
 Kleinbittersdorf, Germany 
Gaussia glow Juice PJK 
 Kleinbittersdorf, Germany 
Gateway® LR Clonase™ II 
Enzyme mix 
Life Technologies 
 Karlsruhe, Germany 
QuikChange® II Site-directed 
mutagenesis Kit 
Agilent Technologies 
La Jolla, USA 
Qiagen Maxi Kit Qiagen 
Hilden, Germany 
Qiagen Mini Kit Qiagen 
Hilden, Germany 
QIAquick Gel extraction kit Qiagen 
Hilden, Germany 
QIAquick PCR Purification Kit Qiagen 
Hilden, Germany 
DNeasy blood & tissue kit Qiagen 
Hamburg, Germany 
Qproteome cell compartment 
kit 
Qiagen 
Hamburg, Germany 
KOD HiFi DNA Polymerase Kit Novagen/Merck 
Darmstadt, Germany 
Chemiluminescence kit Applichem 
 Darmstadt, Germany 
2.10 Laboratory equipment 
2.10.1 Electrical Equipment 
2.10.1.1 Cell Culture 
Designation Company 
Bio GARD cell culture hood The Baker Company 
Sanford, USA 
Steril GARD III Advance cell culture hood The Baker Company 
Sanford, USA 
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Function Line incubator Heraeus 
Hanau, Germany 
Sanyo CO2 incubator Sanyo/Panasonic Healthcare  
Wood Dale, USA 
Neubauer Counting Chamber Neolab Migge, Heidelberg, Germany 
2.10.1.2 Centrifugation 
Designation Company 
Fiberlite™ F12-6 x 500 LEX Fixed Angle 
Rotor 
Thermo Scientific 
Waltham, USA 
Fiberlite™ F13-14 x 50cy Fixed Angle 
Rotor 
Thermo Scientific 
 Waltham, USA 
TFT65 Fixed Angle Rotor Thermo Scientific 
Waltham, USA 
SW41-Ti Rotor Beckman Coulter 
Krefeld, Germany 
Refrigerated Sorvall RC6+ centrifuge Thermo Scientific 
Waltham, USA 
Refrigerated table-top centrifuge 5417R Eppendorf 
Hamburg, Germany 
Table top centrifuge 5415C Eppendorf 
Hamburg, Germany 
Megafuge 1.0 centrifuge Heraeus 
Hanau, Germany 
2.10.1.3 Store 
Designation Company 
Liebherr Comfort Liebherr 
Biberach, Germany 
Liebherr MedLine Liebherr 
Biberach, Germany 
Liebherr Premium Liebherr 
Biberach, Germany 
Liebherr ProfiLine Liebherr 
Biberach, Germany 
Ultra-low freezer Heraeus 
Hanau, Germany 
Nitrogen tank  Messer 
Krefeld, Germany 
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2.10.1.4 Microscope 
Designation Company 
Will Wilovert Wilovert Hund 
Wetzlar, Germany 
Microscope for cell culture  Diavert Leitz 
Wetzlar, Germany 
Zeiss Cell Observer Zeiss 
Jena, Germany 
2.10.1.5 Plates Reader 
Designation Company 
Wallac Work Station Perkin Elmer 
Norwalk, USA 
Multiskan GO Thermo Scientific 
Waltham, USA 
Gel Doc EZ Imager BioRad 
Munich, Germany 
2.10.1.6 Electrophoresis 
Designation Company 
Polyacrylamide Gel 
Electrophoresis Chamber 
Hoefer, San Francisco, USA 
XCell SureLock™ Mini- 
Cell Electrophoresis 
System 
Thermo Scientific 
 Schwerte, Germany 
Transblot SD chamber BioRad, Munich, Germany 
Agarose electrophoresis 
chamber 
BioRad 
Munich, Germany 
Electrophoresis power 
supply ST PS 305 
Gibco BRL, Eggenstein, Germany 
2.10.1.7 Water baths, shakers and mixers 
Designation Company 
GFC Waterbaths Grant Instruments 
Cambridge, UK 
Bacterial culture shaker AG 
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Informs Bottmingen, Switzerland 
Combimage Red/RET 
magnetic stirrer 
IKA 
Staufen, Germany 
Test-tube-rotator Snijders Scientific 
Tilburg, Netherlands 
IKA RW 20 Digital Dual Range 
Mixers 
IKA® LABORTECHNIK JANKE & KUNKEL, 
 Staufen, Germany 
Thermomixer 5436 Eppendorf 
Hamburg, Germany 
Thermomixer comfort Eppendorf 
Hamburg, Germany 
Duomax 1030 shaker Heidolph 
Schwabach, Germany 
Table-top Shaker GFL 
 Burgwedel, Germany 
Vibramax-VXR IKA Staufen, Germany 
Vortex Genie 2TM Bender and Hobein 
Ismaning, Germany 
2.10.1.8 Dot Blot 
Designation Company 
Stratagene's Dot Blot chamber Stratagene 
 California, US 
Laboratory Pumps BioRad,  
Munich, Germany  
Silicone Vacuum Grease Beckman Coulter GmbH 
Krefeld, Germany 
2.10.1.9 Others 
Designation Company 
Integra pipet boy Integra Biosciences GmbH 
 Fernwald, Germany 
800 W microwave Bosch 
Gerlingen-Schillerhöhe, Germany 
Ice maker Hoshizaki 
Willich-Munchheide, Germany 
Impulse Sealer RNS Corp 
 Taipei, Taiwan 
MicroPulser Electroporator BioRad 
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Munich, Germany 
MilliQ ultra-pure water unit Millipore Merck 
 Darmstadt, Germany 
Nanodrop spectrophotometer PegLab 
Erlangen, Germany 
pH meter Sartorius 
Göttingen, Germany 
Sartorius scale Sartorius AG 
Göttingen, Germany 
Western Blot developing machine Agfa 
Mortsel, Belgium 
Analytical Balance ME204E Mettler Toledo GmbH 
Zwingenberg, Germany 
2.10.2 Common use Equipment 
Designation Company 
1.5 mL and 2.0 mL microcentrifuge tubes Eppendorf 
Hamburg, Germany 
10mm cover slips Thermo Scientific 
Waltham, USA 
10 cm culture plates Greiner 
Frickenhausen, Germany 
15 mL reaction tubes TPP 
Klettgau, Switzerland 
14 mL BD falcon round-bottom tube BD biosciences 
2 Oak Park, Bedford, USA 
25, 75 and 150 cm2 Tissue culture flasks TPP 
Klettgau, Switzerland 
50 mL reaction tubes Greiner 
Frickenhausen, Germany 
6, 10 and 15 cm cell culture dishes Sarstedt Inc. 
Newton, USA 
6-, 12-, and 24-well test plates TPP 
 Klettgau, Switzerland 
96-well LIA plate Greiner 
Frickenhausen, Germany 
96-well plate Costar Corning, USA 
Ultracentrifuge tubes (TFT65) Beckman Coulter GmbH 
Krefeld, Germany 
Ultracentrifuge tubes (sw41) Beckman Coulter GmbH 
Krefeld, Germany 
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Cell lifter Costar Corning 
Chemiluminescence films GE Healthcare Limited 
Buckinghamshire, UK 
Cryo tubes, 2 ml Roth 
 Karlsruhe, Germany 
Electroporation cuvettes (25 x 2 mm) Peqlab 
Erlangen, Germany 
Glass slides Thermo Scientific 
Waltham, USA 
Inoculating loop Greiner 
Frickenhausen, Germany 
One-time use filter, 0.2/0.4 μm Renner 
Dannstadt, Germany 
Parafilm “M” American National Can 
Chicago, USA 
Pipette tips Nerbe plus GmbH 
Winsen/Luhe, Germany 
Pipettes (1000, 200, 100, 20, 10 and 2 μL) Gilson 
Middleton, USA 
Syringes and needles BD Franklin Lakes, USA 
Whatman filter paper 3MM paper Schleicher & Schuell 
 Dassel, Germany 
2.10.3 Software 
Designation Company 
Microsoft Windows XP, 8.1 
 
Microsoft 
Redmont, USA 
Clone Manager 9.0 for Windows Scientific & Educational Software, 
 Cary, USA 
Microsoft Office 2003, 2010 Microsoft 
 Redmont, USA 
GraphPad Prism 6.0 GraphPad Software 
La Jolla, USA 
Wallac 1420 Workstation Perkin Elmer 
Norwalk, USA 
ImageJ 1.40 NIH 
Bethesda, USA 
Citavi 5 Swiss Academic Software GmbH 
Wädenswil, switzerland 
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3 Methods 
3.1 Cultivation and manipulation of cells 
3.1.1 Cultivation and manipulation of prokaryotic cells 
3.1.1.1 Cultivation and storage of competent cell 
Glycerol stock or single colony was transferred to liquid LB medium 
supplemented with the respective antibiotics (Amp+, Kana+), and then shaken 
at 200rpm overnight at 37°C. For long-term storage of bacteria containing the 
transformed plasmid, glycerol stocks (2.1.4.3) were prepared with 0.3mL sterile 
glycerol and 1 mL of the overnight bacteria culture and stored at -80°C for 
further use. 
3.1.1.2 Preparation of electrocompetent cell 
MXDH10 E. coli bacteria were used for preparing electrocompetent cells (2.1.2). 
The glycerol stock was transferred to 25mL LB medium without antibiotics and 
shaken at 200rpm overnight at 37℃. Medium culture with 5mL were added to 
400mL LB medium the following morning and shaken at 37℃ 200rpm until the 
culture OD600 reached 0.5-0.6 (2.10.1.7), and then chilled on ice for 30min. 
After harvesting and centrifugation the culture was shaken at 6000rpm in 10 
min at 37℃ in a round-bottom tube, the pellet was resuspended in 30mL 
ice-cold H2O and then transferred to a dialysis bag to dialyze in H2O overnight 
at 4℃. On the third day bacterial cells were harvested by centrifugation at 
4000rpm for 10min at 4℃ and resuspended in 600μL ice-cold 10% glycerol 
solution. All the procedures were performed on ice. Aliquots of 40μL were 
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stored at -80℃ for further use. 
3.1.2 Cultivation and manipulation of eukaryotic cells 
3.1.2.1 Cultivation and storage of mammalian cell lines 
All mammalian cell lines were cultivated in the environment of 37℃, 5% CO2 
and 90% humidity. The cells were passaged when they reached around 90% 
confluency. Cell culture medium was removed, and the attached cells were 
washed with the 0.25% trypsin EDTA (2.1.4.1) to remove residual FBS and 
followed by another addition of trypsin plus incubation at 37℃ to detach the 
cells. The flasks were tapped gently to detach the cells completely and then 
neutralized by adding supplemented medium. After centrifugation 
(1900rpm/5min), the pellet was resuspended in 10mL supplemented medium 
and extract 1mL suspension into new flask, then complemented medium in an 
adequate volume was added. 
For preparing cryo-stocks, the cells at a confluency of about 80% in 150cm2 
culture flask were harvested by trypsinization and centrifugation. The cell pellet 
was resuspended in 3mL cryomedium (2.1.4.3) after centrifugation and then 
aliquoted into 3x 2mL cryotubes. The cells were stored in a cooling chamber 
with isopropanol at -80℃ for at least 24h and then transferred to liquid nitrogen. 
To thaw cryopreserved cells, the tube containing the cells was incubated a in a 
37℃ water bath immediately until most of the suspension was thawed and 
then transferred to a 15mL Falcon tube containing 10mL supplemented 
medium and centrifuged. The cell pellet was resuspended again in an adequate 
volume medium and moved to a new flask.  
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3.1.2.2 Transfection of mammalian cell lines with 
polyethyleneimine (PEI) 
For the transfection in a 6-well plate, 0.8-2.4x105 cells per well were seeded in 
1mL supplemented medium (Table 1) and cultivated for 24h. For preparing the 
transfection mix for a 6-well plate, 10μL H2O were transferred into a 2mL 
Eppendorf tube as well as 1.5μg DNA (2.2.1), 0.25mL unsupplemented DMEM 
and 5μL PEI transfection reagent followed by 10sec vortex and incubating at 
RT for 10min. After incubation, 0.75mL supplemented medium were added to 
this transfection mix and vortexed again. The transfection mix was added onto 
the cells after removing the medium and incubated at 37℃, 5% CO2. Four-14h 
after transfection the transfection mix was removed from the cells and fresh 
supplemented medium was added. The cells were cultivated and were ready to 
be used after 48h. 
Table 2. Overview of the transfection procedure in different formats 
Cell 
Culture 
Plate 
H2O 
Volume 
(μL) 
Cell Number  
(cell/well) 
DNA 
amount 
(μg) 
ΦDMEM 
(mL) 
PEI 
Volume 
(μL) 
Full 
DMEM 
(mL) 
24-well 
plate 
2.5μL 2.0-6.0 x104 0.4μg 0.07mL 1.3μL 0.2mL 
12-well 
plate 
5μL 0.4-1.2 x105 0.8μg 0.13mL 2.5μL 0.4mL 
6-well plate 10μL 0.8-2.4 x105 1.5μg 0.25mL 5μL 0.75mL 
10cm dish 61.5μL 2-3 x106 10μg 1.6mL 31μL 4.6mL 
15cm dish 185μL 6-8x106 27μg 4.6mL 93μL 13.8mL 
3.1.2.3 Transfection of mammalian cell lines with siRNA  
All Negative control siRNA and siRNAs targeting the SUMOylation pathway 
were purchased from Qiagen (Hamburg, Germany). The siRNA knockdown 
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was performed on 2.5x104 HeLa cells seeded in 0.5mL supplemented medium 
in a 24-well plate (Table 2). The transfection mix was prepared by dilution of 
37.5ng siRNA (0.3µL siRNA) (2.2.3) and 3μL HiperFect transfection reagent in 
100μL unsupplemented medium and incubated at RT for 10min. The 
transfection mix was added drop-wise to the cells evenly and cultivated the 
cells 48h. Thereafter the siRNA knockdown-cells were ready for harvesting or 
virus transduction. 
Table 3. Overview of the siRNA transfection procedure in different formats 
Cell 
Culture 
Plate 
Volume of 
medium in 
cell 
(mL) 
Cells Number  
(cell/ well) 
siRNA 
amount 
(ng) 
HiperFect  
Reagent 
(μL) 
Final siRNA 
volume 
(μL)  
24-well 
plate 
0.5mL 2.5x104 37.5ng 3μL 100μL 
12-well 
plate 
1.1mL 8x104 75ng 6μL 100μL 
6cm dish 4mL 3.0x105 256ng 20μL 100μL 
3.1.2.4 Induction of a stable cell line with doxycycline  
To overexpress the stably transfected myc-Gam1 protein, HeLa-Gam1 cells 
(Kindly provided from Susanna Chiocca) were treated for 6~12h with 50 mg/mL 
doxycycline (final concentration is 50ng/μL) after seeding and attaching. 
3.2 Molecular biology methods 
3.2.1 Polymerase chain reaction (PCR)  
The Polymerase chain reaction (PCR) was performed to amplify DNA 
fragments and clone them into destination vectors. The DNA of interest was 
amplified from template DNA plasmid that could contain different restriction 
sites or necessary additional sequences with the help of primers. The primers 
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were designed using Clone Manager CMSuite9 and ordered from MWG 
Eurofins in Ebersberg of Germany. All PCRs were performed using the KOD 
HiFi DNA Polymerase Kit from Novagen/Merck (2.2.4), according to the 
manufacturer´s instructions (table 3 and 4). The annealing temperature, as well 
as the number of DNA amplification cycles, depended on the Tm value of 
primers and were also optimized under different conditions. 
Table 4. Constituents of PCR reaction mix and volumes 
Component Volume (50μL) 
template DNA  (20-50ng) 1μL 
10x KOD Buffer #2 5μL 
dNTPs (2.5mM each) 2μL 
MgCl2 (25mM) 2μL 
Fwd Primer (100μM) 1μL 
Rev Primer (100μM) 1μL 
KOD Polymerase 1μL 
H2O Add up to 50μL 
Table 5. Standard PCR program for KOD HiFi Polymerase Kit 
Process Temperature Time Cycles 
Pre-denaturation 
98℃ 
3min  
Denaturation 
98℃ 
20 sec 
30 cycles 
Annealing 
60℃ 
10 sec 
Extention 
72℃ 
25 sec 
Stabilization 
72℃ 
5 min  
Hold 
4℃ 
∞  
3.2.2 PCR product purification 
The PCR products were purified after the polymerase chain reaction by 
removing all buffers and enzymes for next experiments, e.g. digestion (3.2.8) or 
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ligation (3.2.8). The reaction was performed using QIAquick PCR Purification 
Kit (2.9), following the manufacturer’s protocol.  
3.2.3 StrataCloneTM Blunt TOPO cloning  
The cloning of blunt end PCR products into the TOPO vector was carried out 
using the StrataClone Blunt PCR Cloning Kit (2.9) from Stratagene. It was 
performed according to manufacturer´s instructions.  
3.2.4 Gateway cloning  
Genes of interest were provided as complete Gateway®-compatible 
entry-vectors to shuttle into a destination vector with the LR Clonase™ II 
enzyme mix. All the reactions were done using the Fast Gateway® LR protocol 
(2.9). It was performed according to manufacturer´s instructions. 
Table 6. Constituents of Gateway Clone reaction mix and volumes 
Component Volume 
Entry clone (50-150ng) 1-7μL 
Destination vector (150ng/μL) 1μL 
TE Buffer up to 8μL 
LR Clonase™ II enzyme mix 2μL 
The reaction was processed at 25°C for 1hr followed by the treatment with 1μL 
proteinase K at 37°C for 10min to stop the reaction. 1μL of the LR reaction was 
transformed into 40μL electrocompetent bacteria and resuspended in 500μL LB, 
shaken at 37°C for 1h, followed by spreading on agar plates with the 
appropriate antibiotic and obtain colonies at 37°C overnight. Colonies were 
picked and cultivated for DNA plasmid extraction, restriction digests and 
sequencing to confirm correct insertion. Glycerol stocks of the correct colonies 
were prepared and stored at -80°C. 
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3.2.5 Site-directed mutagenesis QuikChange® cloning 
To mutate the nucleotide of interest in the sequence, a pair of complementary 
primers was designed containing the mutation in their target sequence. The 
reaction was performed using the QuikChange® II XL Site-Directed 
Mutagenesis Kit (2.9), It was performed according to manufacturer´s 
instructions. The reaction mix was prepared as follows: 
Table 7. Constituents of QuikChange® cloning reaction mix and volumes 
Component Volume (50μL) 
10x reaction buffer 5μL 
F-Primer  125ng  
R-Primer  125ng 
DNA template 20ng 
dNTPs (2.5mM each) 1μL 
PfuΜLtra High Fidelity DNA 
polymerase (2.5U/μL) 
1μL 
H2O Add up to 50μL 
Table 8. Standard QuikChange® amplification program 
Process Temperature Time Cycles 
Pre-denaturation 
95℃ 
30 sec  
Denaturation 
95℃ 
30 sec 12-18 cycles 
Annealing 
55℃ 
1 min 
Extention 
68℃ 
1kb/ 1min 
Hold 
4℃ 
∞  
* The point mutations need 12 cycles, single amino acid changes need 16 
cycles, and multiple amino acid deletions or insertions need 18 cycles.  
The PCR product was digested with 1μL of DpnI enzyme and incubated at 37°C 
for 1h. 1μL of each treated PCR product was transferred to a 1.5mL Eppendorf 
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tube containing 50μL of the XL1- Blue supercompetent cells and was gently 
mixed and incubated on ice for 20-30 minutes. The bacteria were transformed 
by heat pulsed for 90 seconds at 42°C and then placed on ice for 2 minutes 
followed by adding 500μL S.O.C medium, and tubes were shaken at 250rpm for 
1h at 37°C. 250μL of the transformation reaction was spread on agar plates 
containing the appropriate antibiotic and incubated at 37°C overnight to obtain 
colonies. Colonies were picked and cultivated for DNA plasmid extraction and 
sequencing to confirm correct insertion. Glycerol stocks of the correct colonies 
were prepared and stored at -80°C. 
3.2.6 Agarose gel-electrophoresis  
Agarose gel-electrophoresis (2.4.2) was used to separate and analyze DNA 
fragment by size. The preparative 1% agarose gels contained 0.006% ethidium 
bromide and were placed into an electrophoresis chamber and filled with 1x 
TAE buffer, mixed loading 6x dye and DNA fragments (volume ratio 1:5) which 
were either produced by PCR or enzymatic restriction to cut a specific region of 
the plasmid DNA was loaded onto the gel together with a DNA ladder and  
electrophoresis was run at 120 V for 30 min. For analytical gels, the DNA was 
visualized with UV light at 254 nm wavelength and for preparative gels at 366 
nm to avoid DNA damage. 
3.2.7 DNA extraction from agarose gels  
For purification of specific DNA fragments from an analytical agarose gel, the 
desired bands were cut out with a scalpel and the QIAquik Gel Extraction Kit 
(2.9) from Qiagen was used. The following purification procedure was carried 
out according to the manufacturer´s instructions. The purified DNA was 
analyzed on a mini agarose gel. 
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3.2.8 Enzyme restriction  
To test isolated plasmid DNA for the absence or presence of a specific insert, 
500ng of DNA plasmids were transferred to a new Eppendorf tube. For 
enzymatic restriction a master mix was prepared containing the 2μL of the 
corresponding 10x buffer, 1μL of the specific enzyme/s per reaction as well as 
H2O add up to 20μL. The reaction was incubated at 37℃ 2-3h. To analyze the 
restricted plasmid DNA, 5μL reaction were mixed with 1μL 6x loading dye and 
run on an agarose gel electrophoresis (2.4.2).  
Table 9. Constituents of Enzyme restriction reaction mix and volumes 
Component Volume (20μL) 
10x reaction buffer 2μL 
Enzyme I (20,000U/mL) 1μL  
Enzyme II (20,000U/mL) 1μL 
Plasmid DNA  100-500ng 
H2O Add up to 20μL 
3.2.9 Dephosphorylation of DNA backbone 5’ 
Dephosphorylation is mainly to prevent the self-ligation of the plasmid vector 
and is most commonly used for plasmids for blunt end ligation. Thus, after the 
enzymatic restriction, the 5'-phosphate group of the cleavage vector was 
removed by adding 2 units of calf-alkaline phosphatase (CIP) (2.2.4). The 
reaction was incubated at 37℃ for 15min, followed by a second incubation at 
58℃ for another 15min. The dephosphorylated vector was purified by agarose 
gel-electrophoresis as described. 
3.2.10 Ligation  
Vector DNA and insert DNA were used in a molar ratio of 1:3. The ligation mix 
was prepared according to manufacturer´s instruction from NEB and incubated 
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at 4℃ overnight. 
Table 10. Overview of the ligation mix 
Component Volume (20μL) 
10x T4 DNA Ligase Buffer 2μL 
Vector DNA 0.02pmol 
Insert DNA 0.06pmol 
T4 DNA Ligase 
(400,000U/mL) 
1μL 
H2O  Add up to 20μL 
3.2.11 Transformation of E. coli bacteria 
3.2.11.1 Transformation of E. coli using the heat-shock 
method 
To transform into XL-Blue supercompetent cells (2.1.2), the DNA plasmid was 
mixed with bacteria and incubated for 90 seconds at 42°C in water bath and 
then the reaction was put on ice for 2 minutes, followed by adding 500μL S.O.C 
medium at 37°C for 1h shaking.  
250μL of the transformation reaction was spread on agar plates containing the 
appropriate antibiotic and incubated at 37°C overnight to obtain colonies. 
Colonies were cultivated, DNA plasmid extracted, enzyme digested and 
sequenced to confirm correct insertion. Glycerol stocks of the correct colonies 
were prepared and stored at -80°C. 
3.2.11.2 Transformation of E. coli using the Electroporation  
For the transformation of electrocompetent bacteria, 1μL of the ligation (3.2.10) 
was mixed with 40μL of electrocompetent bacteria and transferred into a cooled 
electroporation cuvette. 2.5 kV for 5ms pulsing was set up for electroporation 
and 500μL of LB-medium were added to the transformed bacteria and the mix 
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was incubated at 37°C for 1h, followed by plating 10-150μL on a LB-agar plate 
with the respective antibiotic and incubated at 37°C overnight. 
3.2.12 DNA extraction from bacterial cultures  
3.2.12.1 Mini-preparation using the alkaline lysis and 
phenol-chloroform extraction  
The bacteria containing plasmid DNA were harvested from 1.5mL culture 
medium in Eppendorf by centrifugation at 13.000rpm for 2min. To resuspend 
the pellet the 100μL glucose (2.4.1) was used and shaken for 10min at RT. 
200μL lysis buffer were added and incubated for 5-10min on ice and followed 
by a 150μL 3M NaAc ice incubation for 5-10min to stop the reaction. Afterwards, 
450μL phenol were added to the lysed cells and the sample was incubated 
5-10min on a shaker at RT, centrifugation at 13,000rpm for 5min. 380μL of the 
supernatant were transferred to a fresh tube which contains 450μL isopropanol 
already. The sample was then incubated at -70℃ for 10min to precipitate 
plasmid DNA followed by centrifugation at 13.000rpm for 30min on ice and 
washed with 500μL 70% ethanol and 500μL 99% EtOH afterwards. After quick 
drying the pellet was resuspended in 50μL H2O and stored at 4℃. This prep 
needs to be treated with RNase (2.2.4) during digesting process. 
3.2.12.2 Mini-preparation using the Qiagen mini-prep kit  
Plasmid DNA isolation was performed by QIAprep Spin Mini Prep Kit cultured 
from 2mL bacteria culture. The preparation of plasmid DNA was performed 
according to manufacturer´s instructions. 
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3.2.12.3 Maxi-preparation using the Qiagen maxi-prep kit  
Plasmid DNA isolation was performed by Qiagen MaxiPrep Kit cultured from 
2mL bacteria culture. The preparation of plasmid DNA was performed 
according to manufacturer´s instructions. 
3.2.13 DNA quantification  
Nanodrop was used to test plasmid DNA concentration. 1μL DNA sample was 
measured in relation to a blank sample. 
3.2.14 DNA-Sequencing  
Sequencing was performed by GATC Biotech in Konstanz, Germany. 
3.3 Protein analysis methods 
3.3.1 Bradford assay  
To make a calibration curve to determine the target protein concentration, 
10μg/μL BSA stock solution was diluted in H2O to get a final concentration of 
2μg/μL as the working solution. The BSA standard was titrated 1:2 in duplicates 
in a 96-well plate, starting with a concentration of 2μg/μL to 0.016μg/μL. H2O 
was used as well as blank within the Bradford assay (2.5.1). The protein 
samples were used in 3 different dilutions (in H2O), by sequential 1:1dilution. 
3.3.2 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE)  
SDS-PAGE was performed to separate different protein according to the 
difference of protein molecular weight. Each sample (Cell lysate or viral 
particles) was mixed with 3x SDS loading buffer (2.6.2.2) and boiled for 10 
minutes at 95°C. 5μL of the denatured cell lysates or 15μL denatured viral 
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particles, as well as protein ladder, were loaded on fixed SDS gel (2.5.2) in 
chamber. Proteins were separated on the SDS gels in 1x TGS running buffer at 
80 V for 30min for the stacking gel and 120 V (2.5.4) for separating gel.  
3.3.3 Western Blot analysis 
The protein has been separated by SDS-PAGE gel (2.5.3). It is necessary to 
transfer the proteins to the solid phase for the further study, so the proteins 
were blotted onto activated PVDF or nitrocellulose (NC) membrane using the 
wet blot (2.10.1.6) method. Three soaked blotting pads were placed into the 
blot module and followed with 1 piece of filter paper, then the gel covered with 
NC or activated PVDF membrane.  Air bubbles were removed by rolling a 
glass pipette over the membrane surface and covered with another filter paper 
afterwards. After another three soaked blotting pads on the top, the blot module 
was closed with the lid and fixed into the X Cell II™ Blot Module. The transfer 
was performed at 30 mV 90min for proteins with a molecular weight around 
80-150 kDa, or 30min for protein smaller than 50 kDa. The membrane was 
blocked for 1h in 5% milk PBS-T at room temperature (RT) on a shaker and 
then incubated with the desired primary antibody (2.6.1) which was diluted in 5% 
PBS-T milk overnight at 4°C. After incubation the membrane was washed three 
times for 10 minutes with PBS-T and incubated for 1h at RT with the diluted 
secondary antibody. Then the membrane was washed three times for 10 
minutes with PBS-T and proteins were detected by chemiluminescent kit (2.9) 
according to the manufacturer’s protocol by adding 0.5 mL of each solution onto 
the membrane and incubate it for 1 minute at RT. The chemiluminescence was 
detected using developing machine (2.10.1.7) in a dark room. 
3.3.4 Dot Blot 
Protein detection using the dot blot protocol is like western blotting in that both 
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methods allow for the identification and analysis of proteins of interest. Protein 
samples are instead spotted onto membranes and hybridized with an antibody 
probe. The nitrocellulose membrane or PVDF membrane activated in methanol 
for 20 min are put together with two pieces of filter papers on the plate which is 
fixed on the base of dot blot chamber and covered with the 96-fine hole cap 
(2.10.1.8) which can allow each sample across the hole. The chamber was 
sealed by parafilm and connected to the pump to suck liquid sample into the 
membrane. The pump was turned on and 5-50µl from each sample or fraction 
was pipetted onto the membrane, the samples could go through the membrane. 
After the membrane becomes dry after several minutes, it was blocked in 5% 
milk PBS-T in RT and shaken for 1h. After blocking, the membrane was 
incubated with the desired primary antibody (diluted in blocking solution) (2.6.1), 
for 2 hours at RT. After primary antibody incubation the membrane was washed 
three times for 10 minutes with PBS-T and incubated for 1h at RT with the 
secondary antibody. Then, the membrane was washed three times for 10 
minutes with PBS-T and proteins were detected using the chemiluminescent kit 
(2.9) according to the manufacturer’s protocol by adding 0.5 mL of each 
solution onto the membrane and incubate it for 1 minute at RT. The 
chemiluminescence was detected using developing machine in a dark room. 
3.4 Immunological methods  
3.4.1 Immunoprecipitation of virus  
To investigate the interaction of AAV and proteins, immunoprecipitation was 
performed using SureBeads™ Protein G Magnetic Beads. 25μL of SureBeads 
per sample were added to a 1.5mL tube to be magnetized and then supernatant 
was discarded. The beads were washed three times by 1mL NET-N buffer with 
1% NP-40 freshly added (2.6.2.2) followed by resuspension and subsequent 
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magnetization. Purified antibody of interest was added to beads in 1% NET-N 
buffer up to 750μL as final volume and incubated on a rotating wheel at 4°C 
overnight. The beads were washed three times with 1% NET-N buffer on 
second day and incubated with a total of 5x 109 purified AAV2 particles 
overnight on a rotating wheel at 4°C. On the third day, the beads containing 
AAV particles were washed three times with 1% NET-N buffer by resuspension 
and subsequent magnetization, then moved into a new tube with 40μL of 1x 
SDS buffer (2.6.2.2). The beads were incubated at 95 °C for 10 min and moving 
the eluent to a new tube which was either loaded directly for analysis via 
western blot (3.3.3) or stored at 20°C for further use. 
 
3.4.2 Immunofluorescence  
To visualize AAV trafficking at different time points after down regulation of 
SUMOylation, indirect immunofluorescence was performed. 4 x 105 
HeLa-Gam1 cells were plated on coverslips in a 12-well plate, and then Gam1 
was overexpressed by Dox induction (3.1.8). AAV2 transduction was performed 
on the HeLa-Gam1 cells with MOI 105 and incubated at 4℃ 1h on shaker. After 
3 times PBS washing, fresh medium was supplemented onto cells and 
transferred to 37℃, 5% CO2. To test the AAV infection in cells at different time 
points, slides were collected at 1h, 3h, 6h, 9h, 12h and 24h incubation at 37℃, 
5% CO2. The slides with cells were washed 3 times 5 minutes with 1x PBS and 
fixed with 2% paraformaldehyde (PFA) (2.6.3) for 15 minutes at RT. The cells 
were quenched in 50mM ammonium chloride (50nM NH4Cl) (2.6.3) twice for 10 
minutes to avoid dye artefacts, then permeabilized in 0.2% Triton-X100 (2.6.3) 
for 10 minutes. Followed by another 3 times washing with 1x PBS the cells were 
blocked in 1% BSA for 1hr at RT. Thereafter the cells were incubated with 
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desired primary antibody (2.6.1) diluted 1:100 in 100μL 1% BSA 1h at 37°C on a 
shaker. The cells were washed 3 times for 5 minutes with 1x PBS and were 
incubated with secondary antibody and DAPI (1:200) diluted in 1% BSA in PBS 
at 37°C for 1 hour. Subsequently the coverslips were washed three times with 
1x PBS and mounted onto slides using mounting medium (2.6.3) before being 
sealed with nail polish. The slides were visualized using the Zeiss Cell 
Observer or confocal microscope and the images were processed using Image 
J (2.10.1.4). 
3.5 Virological methods  
3.5.1 Production of AAV particles in HEK293TT cells  
To produce AAV particles, 5 x 107 HEK293TT cells we plated on five 15cm 
dishes and transfected as described before (3.1.2.2) using the three-plasmid 
system with AAV capsid plasmid, helper plasmid, as well as reporter plasmid 
(2.1.3.1) at a molar ratio of 1: 1: 1 using a total of 135μg plasmid DNA. After 48 
hours the cells were harvested by cell scrapper and collected with medium into 
2x 50mL tube, washing the empty plates to remove the transfected cells 
completely. After centrifugation at 1900rpm for 10 minutes, the medium was 
removed, and the pellet was resuspended by 20mL 1x PBS and centrifuged 
again. The washed pellet was resuspended in 5mL AAV-lysis buffer (2.3.1) 
before undergoing 5 freeze-thaw cycles in liquid nitrogen and 37°C process 
alternately. Benzonase, which was used to degrade all forms of DNA and RNA 
but having no proteolytic activity, was added 1μL (50U/mL) per prep and 
incubated at 37°C for 30 minutes, followed by a centrifugation at 5000rpm for 
10 minutes. The cell crude lysate containing AAV particles was either purified 
immediately or stored in -80°C for less up to one week. 
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3.5.2 AAV particle purification from 293TT cell extracts 
 Five mL crude lysate containing AAV particles were added through a long 
Pasteur pipette into a Quickseal-Tube first, followed by 1.5mL of iodixanol in 
PBS-MK/NaCl, 1.5mL of 25% iodixanol in PBS-MK with 3μL phenol red solution, 
1.5mL of 40% iodixanol in PBS-MK and 3.8mL of 60% iodixanol in PBS-MK with 
5μL phenol red solution (2.3.1). All samples were balanced to 0.000g difference 
with AAV-Lysis buffer and sealed by heating device and centrifuged at 50,000 
rpm for 2 hours at 10°C with rotor TFT65, Accel=9, Decel=1. Lastly, the tubes 
were gently fixed onto a metal stand and poked with a needle from the top to 
relieve pressure and siphon 1mL of AAV particles from 40% iodixanol phase 
using a needle and syringe. The white band in between of 25% and 40% 
iodixanol phase was avoided during collection. Purified AAV particles were 
stored in -20°C or -80°C for the long-term preservation. 
Table 11. Overview of the Iodixanol gradient for AAV particles purification 
Component  PBS-MK/NaCl 
(mL) 
PBS-MK 
(mL) 
Iodixanol 
 (mL) 
Phenol 
red (μL) 
15% phase 1.5mL - 0.5mL - 
25% phase - 1.332mL 0.833mL 3μL 
40% phase - 0.667mL 1.333mL - 
60% phase - - 3.8mL 5μL 
3.5.3 AAV particle separation by continuous sucrose gradient. 
Iodixanol present in AAV particle preparation was removed by desalting spin 
column and before loading on sucrose gradient. Spin desalting column (2.3.2.1) 
was washed 3 times by PBS-MK and spun down with the speed of 
1200rpm/min for 2 mins to remove Iodixanol completely. Beckman mixer was 
used to prepare the 10-30% sucrose gradient, with 4.5mL of 30% sucrose in the 
front groove and 4.5mL of 10% sucrose in behind (2.3.2.2). Setting up the 
speed of the mixer as 90rpm and dropping into a Beckman tube (14 x 89 mm) at 
3 Methods 
60 
 
1drop/2sec. Sucrose gradient can be stored at 4°C less than 2 days. A total of 1 
x 1011 purified AAV capsids was obtained after iodixanol removal and dissolved 
in 1mL PBS-MK which were mixed with 10μL of phenol red and loaded on the 
top of a Beckman tubes which contain 9mL 10-30% sucrose gradient. After 
ultracentrifugation with the rotor SW41 at 160,000g (or 37,000rpm) for 2 h at 
10°C, 400μL fractions were collected and detected by either Dot Blot (3.3.4), 
Western Blot (3.3.3) or viral infectivity assay (3.3.5). 
3.5.4 AAV particle quantification 
AAV particles containing a CMV- firefly reporter gene aliquots were prepared, 
and titer was determined via quantitative real time PCR (by Barbara Leuchs, 
DKFZ, Heidelberg). 
3.5.5 Viral transduction assay (for Firefly and Gaussia luciferase 
assay) 
Viral transduction assay was performed to analyze the infectivity of the viruses 
containing Firefly or Gaussia reporter gene on different cell lines at different 
conditions, e.g. siRNA knockdown treatment (Table 11). For this, cells were 
seeded at least one day prior transduction and incubated at 37°C. The 
transduction was done at different MOIs (103, 104 or 105) depending on the 
experiment (3.1.2.3). Luciferase analysis could be done in 24h transduction 
with a Kit (3.5.7). 
3.5.6 Viral transduction assay (qPCR) 
3.5.6.1 qPCR for time course experiment 
HeLa cells were seeded in 6cm dish with 3x105 and incubated at 37℃, 5% CO2 
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o/n. The next day Scramble or Sae2 siRNA were prepared for knockdown as 
described before and cultured 48h (Table 2). The cells were transduced and 
incubated in 4℃  1h on shaker. After 3 times PBS washing, cells were 
harvested directly (1h) or incubated longer (5h) at 37°C. Cells were harvested 
by scraping or treatment with trypsin and proteinase K (1000μL Trypsin+ 50μL 
Proteinase K). For trypsin and proteinase K harvesting, the cells were treated 
for 30min at 4℃, harvested and washed with ice-cold 1xPBS. Centrifugation 
was performed at 1,900rpm for 5min. AAV vector genomes were quantified by 
qPCR afterwards. 
3.5.6.2 qPCR for subcellular fractionation 
HeLa cells were treated with siRNA and transduced with AAV2 as described 
before (3.5.6.1). After 4°C incubation 1h followed by 3 times PBS washing to 
remove the free AAV2, the cells were incubated at 37°C for 12h. Samples were 
harvested by subcellular fractionation with the Cell Compartment Kit. AAV 
vector genomes were quantified by qPCR afterwards. 
Table 12. overview of AAV transduction in cells 
Experiment Cell number Culture plate MOI Detection 
method  
Untreated 10x104 24-well plate 105 Western Blot 
siRNA KD 10x104 24-well plate 103 Luciferase assay 
siRNA KD 2.0x105 12-well plate 105 IF 
siRNA KD 3.0x105 6cm dish 105 qPCR 
3.5.7 Luciferase assay 
3.5.7.1 Firefly luciferase assay 
The medium was discarded after 24h AAV2 transduction, and 100μL of 
specialized 1x lysis buffer from Beetle Juice BIG Kit (2.9) was added in the 
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24-well plate and shaken for 15 minutes at RT. Subsequently, 20μL of the lysate 
were transferred into white LIA 96-well plate and all samples were triplicated. 
For the firefly luciferase detection, 100μL of Beetle juice BIG Kit (2.9) were 
added to each well and readout after 1min. The luminescence was analyzed via 
the Wallac Work Station (2.10.1.5). 
3.5.7.2 Gaussia luciferase assay 
Unlike the firefly luciferase assay which tests the crude lysate, the 10μL cell 
culture medium was transferred into white LIA 96-well plate and all samples 
were triplicated. For the Gaussia luciferase detection, readout was performed 
after adding 100μL of Gaussia glow juice (2.9) with 1:50 coelenterazine to each 
well and readout was performed after 1min. The luminescence was analyzed 
via the Wallac Work Station. 
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4 Results 
4.1 The role of SUMO as host restriction factors effecting 
AAV transduction 
4.1.1 Knockdown of SUMOylation results in increased AAV 
transduction 
AAV is worldwide used as gene therapy vector in the past years but it is still 
limited by the length of carriable gene fragments as well as the poor virus 
transduction efficiency. In order to find out the host cell factors effecting AAV 
transduction, screening of siRNA libraries was used to identify that putative 
SUMOylation pathway proteins play an important role as AAV restriction factors. 
This work was performed by our colleague Christina Hölscher et al.. The 
genome wide siRNA libraries screen identified the key players of the 
SUMOylation pathway- which are the E1 enzyme: Sae1/Sae2 complex and the 
E2 enzyme: Ubc9. After 48h knockdown in HeLa cells with siRNA targeting 
Sae2 or Ubc9, AAV2 particles encoding firefly luciferase reporter gene driven 
by a CMV promoter was used to transduce the cells for 24h followed by 
harvesting and testing luciferase assay.  
The data shows the Sae2 or Ubc9 siRNA knockdown in vitro increases the 
transduction of AAV2 (Figure 10b), and the protein level detection confirmed 
the decreased amount of Sae2 or Ubc9 in HeLa cells (Figure 10a), thus 
confirming that SUMOylation catalyzing enzyme Sae2 and Ubc9 are restriction 
factors of AAV2 infection.  
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Figure 10 SUMOylation enzyme Sae2 or Ubc9 knockdown increases AAV transduction. 
(a) Sae2 or Ubc9 protein expression was down-regulated by siRNA transfection in vitro. HeLa 
cells were seeded into 24-well plate with 2.5x104/well and transfected with 37.5ng siRNA 
targeting Sae2 or Ubc9 siRNA, and then harvested after 48h to test the protein level, (b) or 
continually transduced by AAV2-CMV-firefly at MOI=1000 for the next 24h. All samples for 
western blot test was treated with 1x SDS loading buffer. Firefly luciferase assay was intended 
for AAV transduction test, and the standard deviation of the mean of three independent 
experiments is indicated.  
4.1.2 Inhibition of AAV transduction by SUMOylation depends on 
the time point of the knockdown 
The previous work carried out by Katharina Henrich indicated that varying the 
time between knockdown and the next infection by 36h, 24h or 12h (all with 
Sae2 knockdown before transduction) still resulted in enhanced transduction 
rates, but all transductions at these three time points are lower than that of the 
48h period between knockdown and AAV infection (data not shown). So, the 
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next challenge was whether knockdown even after AAV infection would still 
influence transduction efficiency. Cells were infected with AAV2-firefly reporter 
for 24 hours followed by Sae2 knockdown for 72 hours. At the same time this 
was compared to the standard protocol of knockdown before AAV infection, in 
which a Sae2 knockdown for 24h or 48h was accompanied by AAV infection 
and the luciferase assay was performed at 72h. The data shows no increase in 
AAV2 transduction efficiency when infection was done before siRNA 
knockdown (Figure 11a). The kinetics of Sae2 siRNA knockdown shows the 
amount of Sae2 protein decreased over time, and this was indicated by western 
blot and analyzed by ImageJ (Figure 11b).  
 
Figure 11 Influence of the time point of Sae2 knockdown on AAV transduction. (a) Sae2 
knockdown after infection have no effect on transduction efficiency. HeLa cells were seeded 
into 24-well plate with 2.5x104/well and transfected with Sae2 or Scr siRNA as described 
before. AAV2-firefly MOI=1000 was prepared and transduced before (-24h) or after siRNA 
transfection (+24h, +48h). (b) To test the kinetics of Sae2 knockdown, HeLa cell were 
transfected with 0.3ul Sae2 or scrambled siRNA and samples were washed with 1x PBS 
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before harvesting at different time points. Sae2 protein levels were determined by western blot, 
and time point experiment was quantified by ImageJ. All samples were quantified by Bradford 
and treated with 1x SDS loading buffer and boiled. The graph shows relative expression levels 
normalized for each time point to housekeeping gene alpha-actin and to Sae2 signals of cells 
transfected with scrambled siRNA. 
4.1.3 SUMOylation affects transduction of single stranded and 
self-complementary AAV vectors  
The previous experiments described above were performed with 
self-complementary (sc) AAV2 vectors carrying CMV-firefly reporter genes and 
resulted in around 5 to 7-fold increase in Sae2 or Ubc9 siRNA knockdown. 
These vectors deliver a vector genome into the cells that can anneal to a 
double strand (ds) DNA bypassing the requirement of second strand DNA 
synthesis. Given that wildtype AAV carries single stranded genomic DNA in 
nature, whether SUMOylation also affects single stranded (ss) AAV2 vectors 
was previously undetermined. ssAAV as well as scAAV encoding gaussia 
luciferase (ssAAV2-GL and scAAV2-GL) were used side by side in a 
transduction experiment (Figure 12). Similar results were obtained for Ubc9 or 
Sae2 knockdown, the data show that SUMOylation pathway could affects 
ssAAV and scAAV vectors. 
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Figure 12 Sae2 or Ubc9 knockdown enhances transduction of ssAAV and scAAV 
vectors. HeLa cells were seeded into 24-well plate with 2.5x104/well and transfected with 
0.3ul siRNA targeting Sae2 or Ubc9 siRNA as well as scrambled siRNA, followed by ssAAV2 
or scAAV2 infection with MOI=1000 and tested via the gaussia luciferase assay. The mean 
values and standard deviations of the RLU of three independent experiments were normalized 
for treatment with scrambled siRNA. 
4.1.4 Total SUMOylation activity increases after AAV transduction 
The previous work indicated knockdown of either the E1 or E2 enzymes of the 
SUMOylation pathway results in an increased transduction efficiency of AAV2. 
However, it is interest to know whether AAV infection would also affect total 
SUMOylation activity in the host cell. Domingues et al. determined the 
SUMOylation activity increased after influenza A virus (IAV) with the type 
A/WSN/33 infection in A549 cells (Domingues et al. 2015). Therefore, influenza 
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A virus was used to infect A549 cells as positive control to see whether AAV 
transduction enhanced SUMO activity in A549 cells, as well as HeLa cells, in a 
similar manner.  
A549 and HeLa cell lines were infected/transduced by IAV with 5 PFU/cell or 
AAV2 with MOI=100000, and samples were harvested at 4h, 8h and 24h 
post-infection. The data shows that SUMO2/3 protein (including SUMO2/3 
molecules and SUMO conjugates) increased over time after AAV transduction, 
which indicated the similar trend with SUMO level after IAV infection in A549 
cell. At the same time, the data revealed SUMO2/3 protein levels in HeLa cells 
increased significantly over time after AAV2 infection as well (Figure 13).  
 
Figure 13 Total SUMOylation activity increases after AAV transduction. HeLa or A549 
cells were seeded into 24-well plate at 1x 105/well and incubated with either mock (PBS), IAV 
with 5 PFU/cell, or AAV2 vectors at MOI=10000 for 1h at 4°C. After washing to remove the free 
virus, cells were transferred into 37°C and harvested after 4h, 8h, 24h incubation. All samples 
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were quantified by Bradford and harvested with 1x SDS loading buffer. 
4.2 SUMOylation influences infection efficiency by 
affecting the AAV capsid 
4.2.1 AAV2 particles can be SUMOylated 
Previous work showed the knockdown of SUMOylation enzymes E1 of E2 
siRNA could increase AAV transduction in vitro, but how the SUMOylation 
pathway influences AAV was unidentified. To determine the target of 
SUMOylation, the AAV capsid is hypothesized as the target of SUMOylation 
and I tried to find out whether SUMO proteins could conjugate the AAV particles 
capsid directly.  
VP1 (87 kDa), VP2 (73 kDa) and VP3 (62 kDa) proteins assemble to form the 
AAV capsid. AAV particles production was performed by co-transfecting 3 
plasmids into HEK293TT cells (AAV2 VP plasmid which encodes the capsid 
proteins, PDGΔVP helper gene which provides different helper functions to 
produce the particles, as well as the ITR- firefly-ITR reporter gene which allows 
a read out of AAV transduction) and purifying via iodixanol/PBS-MK gradient. 
The hypothesis is that during the AAV production in HEK293TT cells, the intact 
mature AAV2 particles are already modified with SUMOylation, means the 
purified AAV2 particles could be detected with SUMO directly. 
When the purified AAV2 particles were probed with an anti-SUMO antibody, a 
band around 85kDa was detected (Figure 14a), and this can be reproduced 
with different batches of AAV2 preps (Figure 14b). To confirm this was a specific 
band and not a contaminating protein from the AAV production process, purified 
AAV particles were immune precipitated by different antibodies: The human 
papillomavirus-specific antibody K18L2 (as negative control), intact AAV2 
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particle capsid-specific antibody A20, and SUMO1 polyclonal antibody, and 
then tested by western blot. SUMO can be detected on purified AAV2 particles 
after A20 pull down, and in the other way around AAV capsid protein could be 
detected in a SUMO1 pull down. The presence of the SUMO-specific band only 
in the AAV lane and not with Human Papillomavirus 58 (HPV58) plus the lack of 
a SUMO band in the K18L2 pull down confirms the specificity of the SUMO 
protein conjugation to AAV particles (Figure 14c).  
 
Figure 14 AAV2 purified particles SUMOylation specificity confirmation. (a) Purified 
AAV2 particles can be SUMOylated after the viral production process. AAV2 particles were 
harvested from transfected HEK293TT cells and purified by iodixanol gradient. These purified 
AAV particles were mixed with 3x SDS loading buffer and boiled, and 5x108 particles were 
loaded for western blot test. Primary antibody B1 was used to detect AAV2 capsid proteins 
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VP1, VP2, VP3, and α-SUMO2/3 antibody for SUMO detection. (b) VP conjugated SUMO was 
detected on different batches of purified AAV2 particles. Purified AAV2 particles were prepared 
as described before and western blot shows the VPs and SUMO detection. (c) After A20 
antibody pull down, SUMO can be detected on purified AAV particles, meanwhile SUMO1 
antibodies are able to pull down AAV2 particles. Samples were treated as described before 
(3.4.1).  
4.2.2 AAV2 particles cannot be SUMOylated in a SUMO-inhibited 
cell line  
Given the above result it appears that purified AAV2 particles were already 
SUMOylated during the virus production process. Therefore, whether the 
produced AAV2 from SUMO-impaired cell line could be SUMOylated or not 
needs to be challenged.  
HeLa-Gam1 cell are an inducible HeLa cell line whereby the Gam1 protein 
(with Myc-tag) of the adenovirus CELO is expressed after 50ng/ml Doxycycline 
(Dox) induction. The Gam1 protein interferes with the activity of E1 enzyme 
(Sae1/Sae2) inhibiting the SUMOylation pathway, and thus it is utilized here to 
block the SUMOylation and produce AAV2 particles in this cell line to see 
whether the produced particles can be SUMOylated. The SUMO-specific band 
seen before in western blot when particles were produced in regular cells was 
no longer observed in virus produced from induced HeLa-Gam1 cells (Figure 
15). The data provides further evidence that in normal cells AAV particles are 
SUMOylated. 
4 Results 
72 
 
 
Figure 15 SUMO cannot be detected on purified AAV2 particles produced in Gam1 
expressing (SUMO inhibited) cells. 5 x 106 HeLa-Gam1 cells were seeded in 5x 15cm dish 
and cultured until cells attached completely, followed by a 12h 50ng/ml Doxycycline incubation. 
The medium mixed with doxycycline was removed before 3-plasmid transfection to produce 
AAV particles and changing new fresh medium after transfection 4-5h. AAV2 particles were 
harvested in 48h and purified by iodixanol gradient. There were 5x108 particles loaded for 
western blot test. Primary antibody B1 was used to detect AAV2 capsid protein VP1 VP2 and 
VP3, and α-SUMO1 and α-SUMO2/3 were used for SUMO detection. 
4.2.3 Empty AAV2 particles are SUMOylated to a higher extent in 
comparison to full AAV2 particles  
During the AAV full particles production process there are still 10%- 20% empty 
AAV particles contained in the products (Benskey et al. 2016), which means the 
‘full AAV particles’ production utilized 3-plasmids transfection are not the pure 
full AAV particles but contaminated with empty AAV. It was obtained that empty 
AAV2 particles might be more efficiently be SUMOylated than full particles 
(Figure 16a). To determine whether full AAV2 or empty AAV2 are SUMOylated, 
sucrose gradient sedimentation was used to separate the empty AAV particles 
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from the produced ‘full AAV particle’. Thereafter AAV particles were detected by 
dot blot and western blot.  
Full AAV particle is always heavier than empty AAV because of the 
DNA-containing. After sucrose gradient sedimentation, the purer full AAV 
particles gather in 110S area, and the contaminated empty AAV from 
production are more likely to stay in 60S (Figure 16b, upper layer). A total of 24 
fractions (400ul/sample) were harvested from the sucrose gradient and 
detected by dot blot. The data shows all AAV particles appeared in the fractions 
in #4 ~ #13 (Figure 16b, upper layer). In order to determine where accurately 
the purer empty AAV particle was in the sucrose gradient, the complete empty 
AAV particles (without AAV reporter) were centrifuged in the sucrose gradient 
as a reference , and most of the empty particles were detected in the fractions 
in #9 ~ #12 in 60S area (Figure 16b, bottle layer). It confirms the purer AAV full 
particles are more inclined to appear in the fractions close to #4~#7 and empty 
particles are in #8~#13. 
In order to know whether the empty AAV particles in fractions are indeed 
SUMOylated to a higher extent in comparison to full AAV2 particles, fractions 
#1~#15 were picked out and tested by western blot with anti-SUMO1 detection 
(fractions from #16 ~ #24 were indicated had no AAV particles exist). Fractions 
#10, #11, #12 showed the obvious SUMO signals stronger than others (Figure 
16c). In the meanwhile, firefly luciferase assay indicates the fractions #10, #11, 
#12 which had weak infectivity were the empty AAV (Figure 16d). These data 
indicated the empty AAV particles SUMOylation are more extensively than full 
particles.  
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Figure 16 Empty AAV2 particles are SUMOylated more than full (DNA-containing) AAV2 
particles. (a) Empty AAV2 particle shows higher extent to be SUMOylated than full particles. 
There were 5x108 AAV particles purified from iodixanol mixed with loading buffer for western 
blot test. B1 and α-SUMO1 antibody were used for AAV2 capsid and SUMO1 protein detection, 
respectively. (b) The confirmation of full particles and empty particles in sucrose gradient 
fractions. Dot blot assay confirmed the full particles were in the fractions #4~#7 and empty 
AAV2 particles in #8~#13. Primary antibody A20 was used for intact AAV2 particles detection. 
(c) A stronger SUMO modification was shown in the purer empty AAV particles than the purer 
full AAV particles. Full AAV2 fractions, especially for #10, #11 or #12 which were indicated as 
empty AAV particles, shown the stronger SUMO detection. Fractions #1 to #15 were loaded on 
SDS gel for western blot and B1 antibody was used for AAV2 capsid protein detection (d) The 
AAV transduction of each fractions. HeLa cells were seeded in 24-well plate and infected with 
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each fraction for firefly luciferase assay. Standard deviation of three independent experiments 
mean is indicated. 
4.2.4 K142/143 and/or K169 residues play a role in AAV particles 
SUMOylation 
As is known that amino acid lysines (K) is the target of SUMOylation. There are 
34 lysines in AAV2 VP1 and the prediction is that one/some of them might be 
SUMOylated: The comparison of amino acid sequence in serotype AAV1, 2, 3, 
6, 7, 8, 9, 10 and 13 prompts the possibility of the potential lysine (K527) at 
C-terminus of VP could be the candidate, and the modified AAV2 at K532 and 
K549 aa exchange were published because of the enhanced/reduced 
transduction efficiency compared with AAV2 wt in vitro; In addition, some 
lysines in N-terminal of AAV particles VP1/2 are also considered as candidates 
of SUMOylation targets. Base on the above information, the lysine (K) on AAV 
capsid protein was exchanged to Arginine (R) to avoid SUMOylation, followed 
by the modified AAV2 production: in VP1 unique protein sequence (VP1u) - 
K33R, K39R, K51R, K61R, K77R, K92R, K105R, K137R; in VP1/2 common 
region - K142+143R, K161R, K169R; and in VP C-terminal - K527R, K532R, 
K549R (Figure 17a). If any of lysines were the targets, SUMO proteins would 
not conjugate on AAV VP after amino acid exchange, and thus no SUMO could 
be detected after probing the modified AAV2 capsids with anti-SUMO antibody. 
The data shows that SUMO can still be detected on the modified AAV2 with 
VP1 unique sequence mutation (K33R, K39R, K51R, K61R, K77R, K92R, 
K105R and K137R) as well as the modified AAV2 with C-terminal mutation 
(K527R, K532R, K549R) (Figure 17b), but the AAV2 bearing the K142/143R 
and K169R exchanges were unable to be SUMOylated (Figure 17b, sample 9, 
11), and the weak SUMO detection of AAV2-K161R was observed. Noticeably, 
K142/143, K161 and K169 are all in the VP1/2 common region. This data 
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alludes that the AAV capsid VP amino acid K142/143, K169 might be 
SUMOylation targets. 
If K142, K143, K169 of VP are the targets of SUMOylation then the enhancing 
effect of modified AAV particles would be lost after SUMOylation impairment. 
Therefore, modified AAV2s transduction were measured and it was expected 
that AAV2-K142/143R and AAV2-K169R transduction have no enhancing affect 
upon knockdown of Sae2 or Ubc9. 
Luciferase assay exhibited the infectivity of modified and wt AAV2 (Figure 17c) 
and the enhancing effect of Sae2 knockdown was partially reduced (from 
~15-fold increasing to ~5-fold increasing) compared with wt AAV2 (Figure 17d). 
However, the enhancing effect was nearly completely disappeared after Ubc9 
knockdown in AAV2-K142/143R and AAV2-K169R transduction (from ~6-fold 
increasing to ~1.7-fold increasing) (Figure 17e). These data demonstrated that 
K142/143 and K169 residues play a role in AAV particles SUMOylation, 
particularly when the SUMOylation pathway impaired via Ubc9 knockdown. 
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Figure 17 SUMO detection of wt and modified AAV2 indicate K142/143 and K169 are not 
SUMOylated, and their transduction efficiency is not greatly affected by SUMO 
knockdown. (a) Schematic illustration of the AAV2 mutants used in the experiments. K (yellow) 
is the wild type amino acid and R (red) is the exchanged amino acid. (b) SUMO was detected 
by western blot from AAV2 wt particles as well as most modified AAV2 except 
AAV2-K142/143R and AAV2-K169R. Purified wt or modified AAV2 particles were prepared for 
western blot. Primary antibody B1 and SUMO1 were used to detect AAV2 capsid SUMO 
protein, respectively. (c) The Infectivity of wt and modified AAV2 after the impairment of 
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SUMOylation via Sae2 or Ubc9 knockdown. (d) The relative ratio of Sae2/scr shows that 
modified AAV2 at K33R, K39R, K51R, K137R, K142/143R, K161R, K169R partially reduce the 
enhancing affect after Sae2 knockdown compared with AAV2 wt. (e) The enhancing effect of 
modified AAV2 K142/143R and K169R nearly completely disappeared after Ubc9 knockdown, 
and the relative ratio decreased to 1.7 and 2, respectively. Standard deviation of the mean of 
three independent experiments is indicated. 
4.2.5 AAV2 capsid protein VP2 is SUMOylated but not VP1  
The data indicated that the K142/143 and K169 of VP which could be targets of 
SUMO are located within the VP1/2 common region. So, the next question is 
whether either VP1 or VP2, or both are SUMOylated in the common region. 
AAV particles encoding the firefly luciferase reporter gene were produced with 
VP1+VP3 (no VP2), VP2+VP3 (no VP1) as well as wt capsid protein. The data 
showed SUMO cannot be detected on AAV2 VP1+VP3 (no VP2) particles but it 
still can be detected on AAV2- VP2+VP3 (no VP1) particles (Figure 18a). As 
expected, luciferase assay data indicated AAV2- VP2+VP3 (no VP1) had no 
infectivity. Although AAV2 wt and AAV2- VP1+VP3 (no VP2) showed similar 
transduction activity, but the enhancing effect of Ubc9 knockdown was reduced 
a lot compared with AAV2 wt (Figure 18b).  
VP1 plays a very important role in AAV trafficking. The AAV2 particles with VP1 
unique region (VP1u) deletion have no infectivity due to the absence of the 
complete phospholipase A2 (PLA2) domain. It was identified that modified 
AAV2 particles at PLA2 domain (76,77HD/AN) are defective for trafficking in a 
step following perinuclear accumulation (Girod et al. 2002). So, because of 
losing VP1, AAV2- VP2+VP3 (no VP1) particles cannot deliver their vector 
genome into the nucleus (Figure 18b, left).  
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Figure 18 SUMO cannot be detected on AAV2- VP1+VP3 particles lacking VP2. (a) AAV2 
particles lacking VP2 are not SUMOylated but AAV2 wt and AAV-VP1 deletion-particles are. 
Wildtype or VP2-lacking AAV2 particles were prepared and loaded for western blot test. B1 
and SUMO1 antibody were used for AAV2 capsid protein SUMO detection, respectively. (b) 
AAV2 wt and AAV2- VP1+VP3 (no VP2) particles infectivity without siRNA treatment were 
similar, but the enhancing effect of AAV2- VP1+VP3 (no VP2) reduced a lot in Ubc9 
knockdown albeit slightly elevated. HeLa cells were transfected with the siRNA targeting Ubc9, 
and then transduced by wt AAV2 or VP2-lacking AAV2 at MOI=1000 in next 24h. Firefly 
luciferase assay was intended for AAV infection test.  
4.2.6 AAV2 capsid protein SUMOylation related to the VP2 spatial 
structure  
AAV is an icosahedral virus and it was proposed that the N-termini of VP1 and 
VP2 were hidden inside the particle. The SUMOylation candidates K142, K143 
or K169 are located within this part of the capsid. So, the hypothesis is that the 
AAV particles can be SUMOylated due to the spatial structure of VP2 capsid 
protein. Based on this assumption AAV2 particles is produced comprising VP1 
and VP3, and either GFP-VP2 or HA-VP2: particle ‘AAV2- VP1/GFP-VP2/VP3’ 
and particle ‘AAV2- VP1/HA-VP2/VP3’. GFP or HA tags were conjugated 
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N-terminally to VP2 capsid protein. Western blot data showed ‘AAV2- 
VP1/GFP-VP2/VP3’ and ‘AAV2- VP1/HA-VP2/VP3’ particles containing 
extended VP2 with either GFP or HA tag are not SUMOylated (Figure 19a). 
Luciferase assay also shows ‘AAV2- VP1/GFP-VP2/VP3’ and ‘AAV2- 
VP1/HA-VP2/VP3’ had similar transduction efficiency compared to AAV2 wt. 
However, the enhancing effect of Ubc9 knockdown was reduced significantly if 
compared with AAV2 wt. (Figure 19b). This experiment was only performed 
once. 
 
Figure 19 AAV2- VP1/GFP-VP2/VP3 and AAV2- VP1/HA-VP2/VP3 capsids are not 
SUMOylated. (a) ‘AAV2- VP1/GFP-VP2/VP3’ and ‘AAV2- VP1/HA-VP2/VP3’ particles are not 
SUMOylated. Wildtype AAV2, empty AAV2 and AAV2-VP3 only particles were purified and 
prepared for western blot. Anti- HA antibody was used for the HA-VP2 detection and B1 was 
used to detect AAV2 capsid protein VP1, VP2 and VP3, and α-SUMO1 was used for SUMO 
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detection. (b) AAV2 wt, ‘AAV2- VP1/GFP-VP2/VP3’ and ‘AAV2- VP1/HA-VP2/VP3’ particles 
infectivity without siRNA treatment were similar, but the enhancing effect of of ‘AAV2- 
VP1/GFP-VP2/VP3’ and ‘AAV2- VP1/HA-VP2/VP3’ particles reduced a lot in Ubc9 knockdown 
albeit slightly elevated. HeLa cells were transfected with Ubc9 siRNA, and then transduced by 
AAV2 wt, ‘AAV2- VP1/GFP-VP2/VP3’ and ‘AAV2- VP1/HA-VP2/VP3’ at MOI=1000 for the next 
24h. Firefly luciferase assay was performed to determine transduction efficiency.  
4.3 The effect of SUMOylation pathway on AAV trafficking 
in vitro 
4.3.1 AAV transduction after SUMOylation knockdown is not due 
to increased binding or uptake 
In general, the AAV transduction process includes cell binding and uptake, 
endocytosis, post-endocytic trafficking, endosomal escape, nuclear 
translocation and single stranded DNA conversion, but the exact step of the 
AAV transduction process that is affected by the SUMOylation pathway is still 
unknown.  
Therefore, whether AAV2 binding and uptake could be the rate limiting step 
affected by SUMOylation is the first question to be answered. To quantify the 
amount of AAV2 particles binding and entering, HeLa cells, which were 
transfected with Scr or Sae2 siRNA as described before, were incubated with 
AAV vectors for 1h at 4°C. After washing cells, free AAV2 were removed and 
AAV bound on the cell surface would be either harvested directly (1h) or 
harvested after incubation (5h) at 37°C. AAV2 genome was then quantified by 
qPCR and the luciferase assay shows the Sae2 knockdown effect on AAV 
transduction was increased over Scr siRNA as before (3.5.6.1). 
Since no increase was observed in the number of transduced cells upon 
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SUMOylation knockdown either in 1h which is AAV2 binding step (Figure 20, 1h) 
or in 5h uptake step (Figure 20, 5h), using different harvesting methods (cell 
scraper, or trypsin/proteinase K treatment) direct to the same experimental 
results. A regular luciferase assay was performed in 24h post-infection in order 
to ensure the impairment of SUMOylation via Sae2 siRNA knockdown (Figure 
10b). The data showed SUMOylation would not restrict early events of cell 
entry of AAV.  
 
Figure 20 Enhanced AAV transduction by inhibition of SUMOylation is not due to 
increased binding or uptake of capsids. HeLa cells were transfected with scr or Sae2 
siRNAs for 48h and then incubated with AAV vectors at MOI=10000 for 1h at 4°C. After 
washing, cells were harvested directly (1h) or incubated for 5h. Cells were harvested by 
scraping or treatment with trypsin and proteinase K. AAV vector genomes were quantified by 
qPCR. The graph shows the mean of two independent experiments with triplicates each. The 
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AAV vector DNA was quantified by qPCR and normalized to the corresponding siRNA control 
(scrambled). 
4.3.2 Inhibition of SUMOylation does not affect the AAV2 vector 
DNA distribution in cell membrane, cytoplasm or nucleus 
Next, whether the AAV2 particles are affected by SUMOylation in different 
cellular components needs to be challenged, e.g. cell membrane, cytoplasm or 
nucleus. HeLa cells were transfected with Scr or Sae2 siRNA as described 
before and then incubated with AAV vectors for 1h at 4°C (to ensure consistent 
binding of AAV on the membrane) and then the free AAV particles were washed 
afterwards. The infected cells were incubated for another 12h to ensure that the 
virus can be distributed in various parts of cellular components, and then 
different cellular fractions (speed 1000g for cytosolic fraction, 6000g for 
membrane fraction, 6800g for nuclear fraction) were harvested using 
subcellular fractionation technique and quantify AAV vector DNA by qPCR 
(3.5.6.2). Luciferase assay was performed as well to show the AAV 
transduction increase indeed after Sae2 knockdown as before (Figure 10b). 
The qPCR data showed Sae2 knockdown did not affect AAV2 vector DNA 
distribution in the membrane, cytoplasm or nucleus fractions, which are still 
10%, 50% and 40%, respectively (Figure 21).  
Remarkably about AAV2 in nucleus. Although there is no detectable effect of 
AAV2 vector DNA in the nucleus after the Sae2 knockdown, it is still unknown 
whether there are any other changes to the intact AAV particles in the nucleus. 
To be specific, the virus particles are uncoated in the nucleus accompanied by 
the DNA release. The nucleus was harvested by subcellular fractionation and 
the DNA amount detected by qPCR, but it is not clear how many AAV particles 
are uncoated in the nucleus and whether released ssDNA was regulated via 
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SUMOylation impairment. Therefore, although qPCR data suggests no effect of 
AAV2 vector DNA in nucleus, the possibility of AAV2 particles (capsid in 
particular) affected by Sae2 knockdown is still existed.  
 
Figure 21 Inhibition of SUMOylation does not lead to gross changes in subcellular 
localization of AAV vectors. HeLa cells were seeded in 6cm dishes and transfected with 
Sae2 or scr siRNAs for 48 h and then incubated with AAV2 vectors at MOI=10000 for 1h at 4°C. 
After washing, cells were incubated for 12 h followed by washing steps. Cells were harvested 
by trypsin and extract cytosol, membrane, and nuclear compartments according to 
manufacturer’s protocol. AAV2 genomes were quantified by qPCR. The graph shows the 
fraction of AAV2 DNA found in the three subcellular fractions cytosol, membrane, and nuclear. 
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4.3.3 SUMOylation inhibition can enhance AAV accumulation in 
the nucleus  
Since I observed the AAV binding and uptake were not the rate limiting steps of 
AAV entry affected by SUMOylation, and the amount of AAV genomes DNA in 
cytoplasmic and membrane fractions are not altered upon SUMOylation 
knockdown, the nucleus is hypothesis as the important place for AAV2 SUMO 
modification. 
HeLa-Gam1 cell was used as the stable cell line which could inhibit 
endogenous Sae1/Sae2 protein after Doxycycline (Dox) induction. The data 
showed that after Dox (50ng/ml) induction, Gam1 protein starts to be 
expressed and could be detected as early as 3h (Figure 22a) after induction 
reaching the maximum after 12 hours. When doxycycline was removed by 
washing Gam1 expression was undetectable after 24h (Figure 22b).   
About the AAV transduction in HeLa-Gam1 cells. HeLa-Gam1 cells were 
induced with doxycycline overnight (12h) which was then removed from the 
cells. This cell line was kindly supported from Susanna Chiocca. After AAV2 
incubation for 1h at 4°C, the cells were washed and transferred to 37°C. Cells 
lysate were harvested after 1h, 3h, 6h, 9h, 12h and 24h for firefly luciferase 
assay. The data showed luciferase could be tested after 6h infection, and the 
enhancing effect of Gam1 inhibition increases with longer AAV transduction 
(Figure 22c).  
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Figure 22 Detection of Gam1 expression in HeLa-Gam1 cells which increases AAV 
transduction. (a) HeLa-Gam1 cells were induced with final concentration 50ng/ml of Dox, 
harvesting cell lysate with 1x SDS buffer after induction 1h, 3h, 6h, 9h, 12h and 24h to test the 
Gam1 protein level against α-Myc antibody. (b) HeLa-Gam1 cells were induced with Dox 
50ng/ml for 12h, after removing dox the cells were harvested in 1h, 3h, 6h, 9h, 12h and 24h. 
All samples for western blot were treated with 1x SDS loading buffer. (c) HeLa-Gam1 cells 
with/without 50ng/ml Dox induction overnight (12h) were infected with AAV2 and firefly 
luciferase assay was tested after 1h, 3h, 6h, 9h, 12h and 24h of transduction. Shown are the 
mean values and standard deviations of the RLU of three independent experiments 
normalized for treatment with scramble siRNA. 
Next, HeLa-Gam1 cells were used to analyze intracellular translocation of 
AAV2 particles. The cells were treated as described before and collected 3h, 6h, 
12h and 24h after AAV2 infection for immunofluorescence (3.4.2), followed by 
intact AAV2 particle antibody A20 detection. The data shows that after Dox 
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induction, the more expression of Gam1 leads to an accumulation of intact AAV 
particles into the nucleus over time when compared to the non- induced 
HeLa-Gam1 cell (Figure 23).  
 
Figure 23 SUMOylation inhibition by Gam1 expression can direct more AAV particle 
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accumulation in the nucleus. HeLa-Gam1 cells were seeded into 24-well plate with 1x 
105/well with cover slips and induced with 50ng/ml doxycycline overnight (12h). After changing 
the Dox-medium, cells were then incubated with AAV vectors at MOI=100,000 for 1h at 4°C, 
followed by 3 times washing to clear away the free AAV particles. Cover slips were collected 
after 3h, 6h, 12h and 24h AAV incubation in 37°C. AAV particles were labeled by primary 
antibody A20 and Alexa 488-conjugated secondary antibodies. DAPI was used as a nuclear 
staining. An average of 100 cells transfected with AAV and each construct were counted and 
classified into the patterns described. 
4.4 SUMOylation is linked to other existing host cell 
restriction factors that affect AAV transduction 
4.4.1 AAV transduction increased in a Daxx knock out cell line 
During the AAV2 trafficking process, the previous data indicated that AAV 
particles binding or uptake were not affected by SUMOylation (Figure 20), and 
the amount of AAV vector genomes in cytosolic fraction shows no affect by 
SUMOylation either (Figure 21, cytosolic). Intriguingly, although the AAV vector 
DNA in the nucleus did not show the difference (Figure 21, nuclear), 
immunofluorescence data indicated more intact AAV particles accumulated in 
the nucleus after SUMOylation knockdown, which prompted us that 
SUMOylation pathway restricts AAV transduction may occurred in the nucleus, 
and some of the nuclear factors may play an important role towards this. 
As a multifunctional nuclear protein, death domain-associated protein (Daxx) 
regulates a wide range of biological processes, including cell apoptosis and 
gene transcription. Daxx could be modulated by SUMOylation for its subcellular 
localization, and it associated with heterochromatin and promyelocytic 
leukemia nuclear bodies (PML-NBs). In addition, the SUMOylated PML by 
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either SUMO1 or SUMO2/3 could redistributes the localization of Daxx protein 
in the PML-NBs, and Daxx protein can be SUMOylated as well (Lin et al. 2006). 
Moreover, the previous high throughput siRNA screen lists the Daxx protein 
with a high z-score 5.39, which indicates the possibility of AAV transduction 
regulation. 
Based on this assumption, the HeLa-Daxx knock out cell line was performed 
with CRISPR/CAS9 system to study AAV transduction and verify whether 
SUMOylation pathway related to Daxx or Daxx-associated proteins to regulate 
viral infection.  
HeLa-Daxx knockout cell line was produced by Robin Njenga and two colonies 
were picked up successfully (HeLa-Daxx knockout cell line 04B and 06B) after 
Daxx knockout specificity confirmation (Figure 24a). Firefly luciferase assay 
shows the AAV2 transduction in HeLa-Daxx knockout cells compared to wild 
type HeLa cells, 5-fold elevated AAV transduction was observed in both cell 
lines, which indicates that Daxx protein is one of the restriction factors that 
affect AAV transduction in vitro (Figure 24b).  
 
Figure 24 AAV2 infectivity enhanced in HeLa-Daxx knockout cell. (a) HeLa control and 
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HeLa-Daxx knockout cells 04B and 06B were seeded into 24-well plate with 1x105/well 
overnight and then harvested and tested for protein amount, (b) or continually transduced by 
AAV2-CMV-firefly at MOI=1000 in next 24h. All samples for western blot were treated with 1x 
SDS loading buffer and boiled at 95°C for 10mins. Firefly Luciferase Assay was intended for 
AAV transduction test, and the standard deviation of the mean of three independent 
experiments is indicated.  
4.4.2 SUMOylation and Daxx may work in the same pathway 
The previous work indicates SUMO and Daxx both could restrict AAV 
transduction. To know whether SUMO and Daxx worked in the same route to 
affect AAV2 transduction, impairment of SUMOylation via Ubc9 siRNA 
knockdown was performed in the HeLa-Daxx knockout cell line and infected 
with AAV2-firefly afterwards.  
Data showed AAV2 transduction in two Daxx knockout cell were higher than in 
control cell line (Figure 25a, three white column). Ubc9 knockdown enhanced 
AAV transduction in varying degrees in HeLa and HeLa-Daxx knockout cells 
(Figure 17a, black column), but the enhancing effect of Ubc9 knockdown was 
significantly reduced compared to HeLa wild type cells (Figure 25b) which 
indicates SUMO and Daxx protein may work in the same route in a sense, and 
the Ubc9 knockdown in HeLa-Daxx knockout cell cannot promote more on the 
basis of elevated AAV transduction. 
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Figure 25 SUMO protein and Daxx protein work in the same pathway controlling AAV 
transduction. (a) AAV transduction in Daxx knockout cell is higher than in control cell line with 
the negative siRNA treatment. Ubc9 knockdown in HeLa-Daxx knockout cell enhance the AAV 
transduction but slightly. (b) The relative ratio of Ubc9/scr showing the transduction of AAV2 in 
HeLa-Daxx knockout cell after Ubc9 knock down has no significantly change compared with 
AAV2 infection in HeLa wt cell, albeit slightly elevated. HeLa and HeLa-Daxx knockout cells 
04B and 06B were seeded into 24-well plate with 2.5x104/well and transfected with 0.3ul 
targeting Ubc9 or scr siRNA, and then transduced by AAV2 wt or AAV mutants at MOI=1000 
for the next 24h. Firefly luciferase assay was intended for AAV infection test. Standard 
deviation of the mean of three independent experiments is indicated. 
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5 Discussion 
5.1 SUMOylation affects AAV transduction in a host cell 
dependent manner 
Adeno-associated virus (AAV) is widely used as a vector for gene therapy due 
to the broad tissue tropism, low immune response as well as the 
non-pathogenicity. However, it is still limited by the poor transduction efficiency 
due to intercellular restriction factors. Therefore, it is of particular importance to 
study the role of host restriction factors with the aim to increase AAV2 
transduction, thereby improving the utilization of AAV vectors for many disease 
treatments in the clinical trial. 
A high throughput siRNA screen had been carried out previously and two 
candidates with very high z-scores, Sae2 and Ubc9, the catalyzing enzymes of 
SUMOylation pathway (Figure 10), were identified as putative AAV restriction 
factors. Sae2 is a subunit of the unique heterodimeric SUMO E1 activation 
enzyme, and Ubc9 is the unique SUMO E2 conjugating enzyme. Compared to 
untreated cells, HeLa cells treated with Sae2 siRNA or Ubc9 siRNA showed 
significantly increased rAAV2 transduction, indicating that the SUMO E1 and 
E2 enzymes are host restriction factors affecting AAV2 transduction (Hölscher 
et al. 2015).  
Many kinds of virus proteins have been confirmed to be SUMOylated, for 
example adenovirus (Ad) core protein V and human papillomavirus type16 
(HPV16) capsid protein L2 (Freudenberger et al. 2018; Marusic et al. 2010). 
Not only SUMOylation affects viral transduction of the host cell, but some 
experiments also showed that viral infection can change the intracellular 
SUMOylation activity. Pal et al. verified that influenza A virus (IAV) infection 
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triggers an increase in the abundance of proteins carrying both, SUMO1 and 
SUMO2/3 modifications (Pal et al. 2011). Base on this discovery, I also 
observed that the AAV2 infection increases the endogenous total SUMOylation 
activity in two different cell lines (Figure 13). It is conceivable that the host cell 
uses the SUMOylation pathway as a protective mechanism in order to resist 
the invasion of AAV, so more and more activated SUMO proteins can act on 
AAV2 to affect the transduction. 
I found that SUMOylation E1 or E2 enzyme (Sae2, Ubc9) siRNA knockdown 
lead to an increase viral infectivity on one hand, and AAV infection can also 
increase global intracellular SUMOylation on the other hand, which seems to 
be a paradox. However, SUMO levels were also indicated to be regulated 
post-transcriptionally (Sahin et al. 2014). It was indicated that the IAV infection 
did not result in the increase of SUMO mRNA content but increase global 
SUMO1 and SUMO2/3 activity (Domingues et al. 2015), so it might be possible 
that AAV2 infection does not cause an increase in intracellular SUMO mRNA 
content either. Therefore, the next experiment should be determining the 
SUMO mRNA content after AAV2 infection via qPCR, as well as the testing 
after different AAV serotypes in different host cell line.  
5.2 What is the target of SUMOylation? 
Interaction of viruses and the SUMOylation pathway can be acting in different 
manners. For example, leukemia virus is SUMOylated on its capsid protein 
(Yueh et al. 2006), or HSV-1 causes a change in viral transduction through the 
SUMOylation of host promyelocytic leukemia protein (PML) and Sp100. So, 
the SUMOylation pathway is considered to restrict AAV transduction by either 
SUMOylating the virus itself (viral capsid/genome) or an endogenous host cell 
factor that interacts with the virus, or both. In this thesis, the AAV2 capsid 
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protein was indeed confirmed as a target for SUMOylation.  
To determine whether AAV capsids can be SUMOylated, purified AAV2 
particles were proven to carry a SUMO modification. The hypothesis is that the 
produced mature AAV2 particles are modified with SUMO already during the 
AAV production in HEK293TT cells. Thus, a pull-down assay of AAV2 particles 
which were purified by iodixanol gradient was performed and a specific SUMO 
signal is seen indicating the AAV2 capsid is the target of SUMOylation (Figure 
14c). This, however, does not answer the question that whether AAV capsids 
are also further SUMOylated during the entry process. Isolation of AAV 
capsids from transduced cells proved to be difficult, therefore this question 
remains open. 
Due to the characteristics of the AAV packaging process, the capsid is formed 
by VP1 VP2 VP3 and accompanied by ssDNA entry into the virus particles 
from 5-fold axis of AAV capsid (DiPrimio et al. 2008; King et al. 2001). As the 
DNA packaging is not a 100% efficient process, empty AAV particles are 
usually present in AAV vector preparations. Empty AAV exhibit some 
properties that are different from those of capsid viruses, e.g. empty capsids 
exhibiting higher thermal stability than full AAV particles (Kronenberg et al. 
2005; Bleker et al. 2005). In addition, I could observe that empty AAV2 
particles are SUMOylated to a higher extent in comparison to full particles, a 
plausible explanation for this would be better accessibility of SUMO target 
sequences within VP (Figure 16).  
According to the analysis of more than 3,600 SUMOylated proteins, the 
classical SUMOylation modification motif found nearby SUMO sites is 
Ψ-K-X-E/D (Hendriks and Vertegaal 2016). Ψ is a hydrophobic amino acid, 
and X is an arbitrary amino acid, and E/D are acidic amino acids. Ubc9 
recognizes the Ψ-K-X-E/D SUMO motif within a target protein and catalyzes 
the interaction with the substrate (Bernier-Villamor et al. 2002). Based on the 
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above information, I analyzed the AAV capsid VP sequence for the presence of 
the core KXE-type motif. The analysis of sequences shows that the AAV2 
capsid VP contains a total of 34 lysines (K) residues, four of them having the 
basal KXE-type of SUMO site: K39, K61, K105 and K527. However, the data 
presented in this thesis indicates that none of these are actually targets for 
SUMOylation. Nonetheless, the Ψ-K-X-E/D is not the only SUMO modification 
motif, but the inverted sequence [ED]XK is investigated as another promising 
motif (Matic et al. 2010). Sequences analysis shows only K532 on the AAV2 
capsid have this inverted sequence.  
In fact, there are ten lysines (K258, K490, K507, K527, K532, K544, K549, 
K556, K665, and K706) at C-terminal of AAV2 VP protein are surface exposed 
(Xie et al. 2002). Lochrie et al. found the modified AAV2 with K527A 
transduction efficiency is 50% lower than wild type AAV2 (Lochrie et al. 2006). 
Li et al. found the modified AAV2-K527E and AAV2-K532E have no 
transduction activity in vitro but much better transduction than wt AAV2 vectors 
in vivo, and the transduction efficiency of AAV2-K549E increased in vivo and in 
vitro up to 5-fold compared with wt AAV2 (Li et al. 2015). But in this thesis the 
lysine at C-terminus of VP were exchanged with arginine (R) because they 
both have side chain which can be positively charged, and the mutants were 
used to produce the AAV2-K527R, AAV2-K532R and AAV2-K549R. The 
infection test shows these three modified AAV2 transduction have no big 
change compared with wt AAV2 without any treatment (Figure 17c, right, white 
column), confirming that different amino acid (A/E/R) after lysine exchange 
could impact the infectivity of AAV2. Since E1 or E2 knockdown still enhance 
the increase of modified AAV2-K527R, AAV2-K532R and AAV2-K549R 
transduction efficiency (Figure 17c, right, black column) and the SUMO signal 
can still be detected on these viruses capsid (Figure 17b), I concluded that the 
VP amino acid K527, K532 or K549 are not the targets of SUMOylation. 
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Not only the lysines on the capsid external surface, but also those located in 
the N-terminus are candidate sites for SUMOylation. During intracellular AAV 
trafficking, the N- terminus of the AAV2 capsid VP1 is exposed to reveal the 
PLA2 domain, caused by the low pH/acidic environment of the endosome or 
lysosome (Girod et al. 2002). So not only the lysine in C-terminal of VP which 
could exposed on the external surface, the lysines in the N-terminal are still 
worth to be challenged even if the N-terminal of VP is hidden inside of the virus. 
Modified AAV2 (the K33, K39, K51, K61, K77, K92, K105, K137 in the VP1u, 
and K142/143, K161, K169 in the VP1/VP2 common region) were produced 
and in fact AAV2-K142/143R and AAV2-K169R were indicated to be 
SUMOylation targets. Interestingly, another modified AAV2-K161R was also 
observed the weak SUMOylation (Figure 17b), which prompted the possibility 
of AAV capsid SUMOylation in the VP1/VP2 common region. 
Multiple proteins which have been confirmed as SUMO substrates even if they 
do not have the basal motifs at all, e.g. Mdm2 protein is SUMOylated at lysine 
K446 (sequence GRPKNGC) which has no SUMOylation consensuses 
sequence but is located within the RING finger domain (Buschmann 2000; 
Johnson 2004); and Daxx protein can also be SUMOylated at lysine K630/631 
(sequence PCKKSR) but not the SUMOylation motif either, means that there 
are still some unknown motifs or mechanisms that could regulate target 
proteins SUMOylation. Although K142/143 and K169 on AAV capsid do not 
contain the Ψ-K-X-E/D or [ED]XK consensus sequences, these lysines are still 
possibly to be SUMOylated (Figure 17a).  
VP1, VP2 and VP3 are being translated from one ORF, so VP1 and VP2 have 
an overlapping sequence which was called VP1/2 common region (from amino 
acid 138 to 202). Lysines K142/143 and K169 are part of this common region 
and modification of either site resulted in the loss of SUMO conjugation (Figure 
17b). Intact AAV particles can be formed with VP1+VP3, or VP2+VP3, or VP3 
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alone in the absence of helper functions and AAV genomes (Warrington et al. 
2004; Girod et al. 2002; Hoque et al. 1999). So, these defective AAV2 with 
SUMO detection indicated the lysines on VP2 are SUMOylation targets (Figure 
18). 
In addition, due to the controversial function of VP2 from the study of 
Muralidhar or Warrington (Muralidhar et al. 1994; Warrington et al. 2004), VP2 
seems to be a good subject for AAV SUMOylation study. I observed that when 
AAV particles were linked with a tag (GFP or HA tag) at the N-terminus of the 
VP2, SUMO proteins were no longer detected on particles, which means the 
free N-terminal VP2 promotes SUMOylation of AAV2 particles, and the AAV2 
capsid SUMOylation depends on the VP2 spatial structure (Figure 19). 
5.3 Which step of the AAV transduction is affected by 
SUMOylation? 
This thesis has provided evidence that the SUMOylation pathway restricts AAV 
transduction, but the exact step of AAV transduction that benefits from the 
impairment of SUMOylation is still unknown. 
AAV2 subcellular trafficking involves multiple steps. First of all, AAV2 particles 
bind to different receptors or coreceptors on cell surface (Pillay and Carette 
2017). In general, the AAV attachment is not recognized as rate limiting steps 
for AAV2 transduction (Nonnenmacher and Weber, 2012), and the data in this 
thesis indeed indicated the SUMOylation does not affect AAV transduction with 
virus binding step (Figure 20, 1h time point). Subsequently, AAV2 particles are 
internalized into the endosomal pathway and the comprehensive microtubule 
network is used for the endosomal AAV2 particle transport. Xiao et al. indicate 
the AAV particles enter the cell and escape from early endosomes within 
10min after infection and viral uncoating occurs about 12 hours post-infection 
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(Xiao et al. 2002). Meanwhile the AAV2 PLA2 domain in VP1 becomes 
exposed in the late endosome or lysosome because of the low pH/acidic 
environment. Therefore, I predict that AAV has experienced endocytosis and 
escape from endosome after 5 hours infection. The date indicate AAV 
transduction does not regulated by the SUMOylation pathway in the first 5h of 
AAV infection (Figure 20, 5h time point). Above all, also the viral particle 
endocytosis and post-endocytic trafficking are always recognized as rate 
limiting steps for AAV2 transduction (Nonnenmacher and Weber, 2012), but 
they are not the bottleneck of AAV transduction regulated by the SUMOylation 
pathway. 
AAV intracellular transport is regulated by the microtubule network as well as 
the trans Golgi network (Xiao and Samulski 2012; Nonnenmacher et al. 2015). 
This thesis shows that during the viral trafficking, the amount of AAV2 particles 
attached on the cell surface or in the cytoplasm does not change after Sae2 
knockdown (Figure 21, membrane and cytoplasm). Besides, AAV virions are 
also known to accumulate in a perinuclear region, followed by slow entry into 
the cell’s nucleus. Thereafter, the AAV2 particles uncoated and release their 
viral DNA, and the second strand DNA synthesis is promoted by the ITRs 
(Nonnenmacher and Weber 2012). It is clear to see that AAV2 transduction 
increases after Sae2 knockdown (Figure 10) and more intact AAV particles still 
accumulate in nucleus after 6h infection (Figure 23). This provides a possibility 
that SUMOylation pathway could restricts the number of particles that reach 
the nucleus, thus in a knockdown condition, more virus gets to the nucleus and 
undergoes uncoating and transduction (Figure 26a). Also given that the data 
collection time point of the experiment was at 12hours, this provides just a 
snapshot and does not rule out that the kinetics in the knockdown condition 
could be different leading to more viral genomes expressed either earlier or 
later (Figure 23).  
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Figure 26 Hypothetical infectious pathway of AAV2 impairment of SUMOylation by Sae2 
knockdown. AAV transduction at normal SUMOylation activity. From AAV2 binding, 
endosome, post-endocytic trafficking and virus escape, perinuclear accumulation, particle 
translocation into the nucleus, followed by viral capsid uncoating and ssDNA release. (a) AAV2 
transduction with impairment of SUMOylation by knockdown of Sae2. In the absence of 
SUMOylating proteins, more capsids reach the nucleus and undergo uncoating and 
transduction. (b) Account of AAV particles coming into the nucleus are same, but Sae2 
knockdown could promote the AAV2 genome ejection from the intact capsid, and the 
remaining empty particle capsid after uncoating exhibited better stability characteristic against 
degradation after uncoating. 
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In addition, if the above assumption is wrong, which means the AAV particles 
account coming into the nucleus are same (Figure 21, nuclear) and they are 
regulated by SUMOylation in the nucleus (Figure 23). Since this thesis is based 
on the scAAV study, the impact of the second-strand DNA synthesis is excluded. 
Therefore, I speculate that SUMOylation may related to the AAV uncoating and 
ssDNA release. 
Until today, there is no study on how AAV2 is uncoated in nucleus, but it is 
identified that parvovirus Minute Virus of Mice (MVM) genome release mainly 
occurs without capsid disassembly (Ros et al. 2006). Viral uncoating and DNA 
release are important rate-limiting steps for virus transduction, and the viral 
genome ejection from the complete intact capsid is wide-ranging in 
non-enveloped viruses (Suomalainen and Greber 2013). More recently, AAV8 
and AAV9 DNA release have been identified that linearized ssDNA could be 
ejected from the complete viral capsid (Bernaud et al. 2018). Therefore, 
combining the results of AAV capsid protein SUMOylation, the other possibility 
is that SUMOylation could not affect the amount of AAV2 particles but instead 
enhance AAV transduction by promoting AAV uncoating and ssDNA release in 
the nucleus (Figure 26b). 
5.4 The Daxx protein affects AAV transduction via the 
SUMOylation pathway 
Daxx is a highly conserved nuclear protein widely distributed in subcellular 
regions such as nucleoplasm, nucleolus, heterochromatin and promyelocytic 
leukemia protein nucleus bodies (PML-NBs) and acts to regulate apoptosis 
and transcription, and DAXX deficiency will lead to the depolymerization of 
PML-NBs (Bernardi and Pandolfi 2007; Borden 2002; Geng et al. 2012). Some 
studies have shown that the Daxx and ATRX, two components of the PML 
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oncogenic domains (PODs), in the form of a complex to represent an intrinsic 
immune mechanism acting as a viral defense against a large number of 
different viruses (Schreiner and Wodrich 2013). Moreover, the previous RNAi 
screen in my lab identified the protein Daxx and ATRX as putative AAV 
restriction factors showed the preeminent ranking No. 27 and No. 108 with 
high z-scores of 5.39 and 3.38, respectively (in total ~20,000 gene) (Hölscher 
et al. 2015). In consequence it reveals the possibility of AAV transduction 
affected by PML-NBs-related proteins.  
SUMOylation is mainly occurs in the nucleus, especially high enriched in 
nuclear bodies and chromatin to regulate chromatin-remodeling complexes 
modification (Wotton et al. 2017). In addition, this thesis shows the possibility 
of AAV2 SUMOylation in the nucleus (Figure 23), so nuclear factors may play 
an important role in AAV transduction process. 
In general, PML SUMOylation (at aa K65, K160 and K490) could distributes the 
localization of Daxx in PML-NBs. PML-NBs will be depolymerized when PML 
protein is not SUMOylated after Ubc9 downregulation, followed by the Daxx 
protein translocate to dense chromatin (Best et al. 2002; Nacerddine et al. 
2005), In the meanwhile, the Daxx protein itself can be SUMOylation as well. It 
was identified that Daxx, the SUMOylation defective mutant, was able to 
interact with PML and co-localized in PODs at K630/631 (Lin et al. 2006; Jang 
et al. 2002). The PODs co-localization mediated by SUMO1 to form 
DAXX-SUMO1-PML complex, which is the supporting structure of PML-NBs 
(Chang et al. 2011; Hecker et al. 2006), and the DAXX in the cytoplasm is 
recruited into PML-NBs by combining with the SUMOylated PML protein. The 
absence of Daxx cause PML-NBs disintegration. Therefore, the AAV 
transduction is predicted to be affected by Daxx and/or PML protein 
SUMOylation. 
Due to the above conjecture, Daxx is considered in this thesis to be involved in 
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the effect of SUMOylation on AAV transduction. The knockout of endogenous 
Daxx leads to the increased AAV transduction (Figure 16). Upon the 
impairment of SUMOylation, especially for Ubc9 siRNA knockdown in 
HeLa-Daxx knockout cell, the enhancing effect of Ubc9 knockdown were 
reduced significantly. This indicates that the Daxx protein works, at least in part, 
in the same pathway with SUMOylation to affect AAV transduction (Figure 25). 
Based on the above data, the AAV2 capsid protein and intracellular factor 
Daxx could be considered as targets of SUMOylation affecting AAV2 
transduction. On one hand, SUMO conjugates to the AAV2 capsid protein 
directly; On the other hand, the results from the AAV2 transduction 
experiments in the presence or absence of Daxx plus or minus SUMO 
knockdown would postulate that the Daxx protein is SUMOylated (Figure 28, 
red box), or the protein associated with Daxx can be SUMOylated thereby 
regulating AAV transduction. Hypothetical model is shown below (Figure 27).  
 
Figure 27 Hypothetical model of SUMOylation interfering with AAV. (a) Target of 
SUMOylation that affects AAV2 transduction is the AAV2 capsid. In general, SUMO protein 
would conjugate to the AAV2 capsid for the inhibition leading to reduced intra cellular transport 
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or uncoating, but the knockdown of enzymes in the SUMOylation cascade results in an active 
form of the AAV2 virus. (b) Target of SUMOylation is the host factors thus affecting AAV 
transduction. PML-NBs will be disintegrated when PML protein is not SUMOylated, and the 
Daxx would translocate from PML-NBs to the dense chromatin; And the absence of Daxx 
protein would also cause the disintegration of PML-NBs to affect AAV2 transduction. 
Since neither of the components (AAV capsid protein at K142/143 and K169, 
Daxx protein) can be determined as the sole target of SUMOylation, the 
synergism of the multiple SUMOylation targets that affect AAV transduction 
needs to be further investigated. The transduction of the lysine-mutant AAV2: 
AAV2-K142/143R and AAV-K169R could be tested in the HeLa-Daxx knockout 
cell line with or without knockdown of Sae2 or Ubc9 (Figure 28). This pre-test 
shows the infectivity of modified AAV2 with K142/143R or K169R infectivity in 
Daxx knockout cell line is lower than wt AAV in wt cells. Although it still has a 
very weak elevated trend, but it reveals the possibility of multiple factors 
cooperation on AAV transduction by SUMOylation regulation. 
 
Figure 28 Multiple factors control AAV2 transduction. AAV wt infectivity in HeLa-Daxx 
knockout cells is lower than in HeLa wt cells, and the modified AAV2 at K142/143R or K169R 
show even lower infectivity in HeLa-Daxx knockout cells. There are two Daxx knockout cell line 
were used for infection test (04B, 06B). Blue box, the comparison of AAV2 wt and modified 
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AAV2 (K142/143R, K169R) transduction efficiency. Red box, the comparison of AAV2 wt 
transduction efficiency in wt or Daxx knockout cell line. Yellow box, the comparison of modified 
AAV2 (K142/143R, K169R) in Daxx knockout cell line. 
5.5 AAV gene therapy  
Gene therapy vectors have been approved in succession around the world. In 
2017, the United States successively approved the listing of three gene 
therapies, two gene therapy programs and one direct-dose gene therapy drug. 
Apart from the latest immunotherapy using CAR-T cells which target 
tumor-associated cell surface antigens, various viral vectors have also been 
studied including lentivirus (LV), retrovirus (RV), and AAV, etc. For reasons of 
long-term gene expression, non-autonomous replication, transduction of 
dividing and non-dividing cells and especially because of the non-pathogenicity 
of the parental wild type AAV, recombinant AAV (rAAV) become a promising 
and meaningful tool in gene therapy. 
Remarkably, AAV vector has been used and shall continue to be used for 
different clinical trials. The AAV vector alipogene tiparvovec (Glybera®) for the 
treatment of familial lipoprotein lipase deficiency is the first AAV-based drug 
licensed in Europe in October 2012 (Salmon et al. 2014). Recently, the US 
Food and Drug Administration (FDA) approved Luxturna in October 2017, 
which is used for the hereditary blindness genetic therapy treatment 
(https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm5894
67.htm). More recently, George et al. reported that the Hemophilia B Gene 
Therapy using AAV on patients was successful for the first time (George et al. 
2017). Also, there are multiple neurological disease clinical trials that are 
ongoing throughout different parts of the world (Deverman et al. 2018). These 
indicate that AAV plays a pivotal role as a promising carrier of gene therapy 
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worldwide. 
Scientists have tried to use some substances along with AAV in order to 
increase the transduction efficiency of AAV in vivo. For example, the 
proteasome inhibitor, Bortezomib is currently approved by the US Food and 
Drug Administration for clinical trial, mainly for the treatment of multiple 
myeloma, and scholars have utilized this chemical compound in AAV gene 
therapy. Monahan et al used Bortezomib to treat dogs with hemophilia 
accompanied by rAAV2 or rAAV8 injection which contained the eighth 
coagulation factor, and they found the single dose of Bortezomib can increase 
their transduction efficiency and return the hemophilia dogs clotting time to 
normal and reduced the bleeding rate by 90% (Monahan et al. 2010). 
However, the toxicity of these chemical compounds needs to be considered 
despite the increase in the rAAV transduction efficiency. For example, 
Bortezomib would cause adverse reactions such as gastrointestinal discomfort, 
peripheral neuropathy, heart failure, etc., so patients have had to reduce the 
dose or even stop treatment (Petrucci et al. 2013; Rampen et al. 2013; 
Voortman and Giaccone 2006). Therefore, the cooperation of chemicals and 
AAV need to be balanced within a safe and effective range. 
To avoid the chemical compound toxicity, I proposed an alternative scheme to 
use a co-infection of two viruses of the same serotype, whereby the restriction 
factors of SUMOylation are eliminated resulting in higher transduction efficacy. 
The unique enzymes (E1 and E2) of the SUMO pathway are restriction factors 
of AAV2 infection in this thesis, and Gam1 was indicated as the inhibitor of the 
SUMO E1 catalytic enzyme, such that the overexpression of Gam1 resulted in 
the increase of AAV transduction. To avoid toxicity caused by chemicals in vitro, 
the AAV2-Gam1 and AAV2-firefly coinfection was performed. The AAV2-Gam1 
coinfected with AAV2-firefly in vitro shows significantly higher transduction than 
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the AAV2- YFP coinfected with AAV2-firefly (control group) and the maximum 
value was observed when the molar ratio of two viruses was 0.5:1 (AAV2-Gam1: 
AAV2-firefly= 1:2). This demonstrates a new direction for AAV vectors for use in 
future clinical trials (Figure 29). 
 
Figure 29 Coinfection with AAV2- Gam1 increases transduction efficacy of AAV2 
vectors. (a) Infectivity of rAAV2-firefly coinfected with control rAAV (AAV2-YFP) and 
SUMO-targeting rAAV (AAV2-Gam1). (b) Infectivity of rAAV2-firefly with different molar ratios 
of SUMO-targeting rAAV, and the best infectivity of rAAV2-firefly is observed at the molar ratio 
of 0.5:1. The molar amount of rAAV2-firefly was kept the same, and coinfected with either 
AAV2-Gam1 or control rAAV2-YFP with different molar ratios.  
This pre-test suggested the possibility of co-infection, i.e. rAAV2-a a gene 
carrying the SUMO inhibitor, and rAAV2-b carrying a target gene. The 
homologous AAV was used to avoid cytotoxicity caused by infection of 
non-homologous viruses. Further experiments should also be performed in 
vitro and in vivo. 
5.6 Conclusion 
In summary, SUMO E1 (Sae2) and SUMO E2 (Ubc9) enzymes are confirmed 
as host cell restriction factors for rAAV2 transduction efficiency, and total 
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SUMOylation activity is enhanced by AAV2 infection.  
To determine the target of SUMOylation, pull-down assays were performed for 
AAV2 particles which indicated that the AAV2 capsid protein is the target of 
SUMOylation. The site-directed mutation and enhanced virus transduction 
show that K142/143 and K169 on VP2 play a role in capsid SUMOylation. In 
addition, the tag-linked VP2 N-terminus resulting in no SUMOylation, indicating 
that the AAV2 capsid protein SUMOylation requires a defined VP2 spatial 
structure. 
Moreover, the increase in AAV2 transduction in Daxx knockout cell line 
indicated that Daxx is another restriction factor of AAV infection. Compared 
with wild type cell line, the enhancing affects after SUMOylation knockdown 
were strongly reduced, which means the Daxx protein and SUMOylation may 
work in the same pathway. So not only the AAV2 capsid protein but also Daxx 
may be a target of SUMOylation. 
AAV2 subcellular trafficking involves multiple steps. SUMOylation does not 
have an impact on the accumulation of AAV2 vector DNA on the cell surface or 
in the cytoplasm after transduction. But pre-limitary data indicates two 
possibilities for SUMOylated AAV2 particles accumulation in the 
perinuclear/nucleus: More AAV2 particles reach the nucleus with the 
impairment of SUMOylation and undergoes uncoating and transduction; 
SUMOylation does not restricts the amount of AAV2 particles in the nucleus but 
enhance AAV transduction by promoting AAV uncoating and ssDNA release 
from the complete viral capsid. 
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6 Summary 
Adeno-associated virus (AAV) is a member of the Parvoviridae family with a 
non-enveloped and icosahedral capsid structure. Recombinant AAVs (rAAV) 
are non-pathogenic with the low immunogenicity and broad cell/tissue tropism, 
thus AAV is wildly used as a gene therapy tool. Currently, many clinical trials 
involving AAV vectors are ongoing and the marketed drug Glybera® was 
approved in Europe in 2012, followed by the Luxturna by FDA approval in 2017.  
However, the limitation of this vector is the poor AAV transduction efficiency. To 
reveal the regulation of the host factors in AAV2 transduction, an RNAi screen 
was performed previously to identify host proteins interfering with AAV2 
transduction. Sae2 and Ubc9, which are key enzymes of the SUMOylation 
pathway, were identified as restriction factors of AAV infection. Similar to the 
ubiquitination, SUMOylation is a post-translational protein modification 
catalyzed by an E1 activating enzyme (consisting of Sae1 and Sae2) and an E2 
conjugating enzyme (Ubc9).  
Further investigations in this thesis confirmed that the impairment of 
SUMOylation via Sae2 or Ubc9 knockdown resulted in a higher AAV 
transduction efficiency, and AAV2 infection can also enhance the total 
SUMOylation activity of host cells. Moreover, SUMOylation affects the 
transduction of AAV vectors with single stranded DNA (ssAAV) and 
self-complementary DNA (scAAV).  
To determine the target of SUMOylation in the AAV life cycle, a pull-down assay 
was performed for AAV2 particles indicating that the AAV2 capsid protein is 
SUMOylated. Site-directed mutagenesis and modified virus transduction 
shows involvement of K142/143 and K169 of VP2 in capsid SUMOylation. In 
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addition, the data suggests that the N-terminus of VP2 needs to be free, as 
addition of protein tags such as GFP or HA abolishes SUMOylation. This 
indicates that the AAV2 capsid SUMOylation has VP2 spatial structure 
requirements. 
Moreover, the observed increased AAV2 transduction in a Daxx knockout cell 
line indicates that Daxx is another restriction factor of AAV. Compared with wild 
type HeLa cell line, the enhancing affects after Ubc9 knockdown in Daxx 
knockout cell line was dramatically reduced, which means the Daxx protein and 
SUMOylation may work in the same or overlapping pathways. Thence, not only 
the AAV2 capsid protein, but also SUMOylated Daxx could regulate AAV 
transduction. 
AAV2 subcellular trafficking involves multiple steps. AAV2 vector DNA in the 
cell membrane and cytoplasmic fractions are not altered after Sae2 knockdown 
indicating that impairment of the SUMOylation-pathway cannot affect AAV 
binding and the intracellular transport and therefore have no influence on AAV 
transduction. Other than this, there are two possibilities for SUMOylated AAV2 
particles to accumulate in the nucleus: SUMOylation pathway could restrict the 
number of particles that reach the nucleus and undergo transduction; 
Alternatively, SUMOylation could not affect the amount of AAV2 particles but 
instead enhance AAV transduction by promoting AAV uncoating and ssDNA 
release in the nucleus.  
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7 Zusammenfassung 
Das Adeno-assoziierte Virus (AAV) gehört zur Familie der Parvoviridae und 
besitzt eine nicht-umhüllte und ikosaedrische Kapsidstruktur. Rekombinante 
AAVs (rAAV) sind nicht-pathogene Vektoren, die eine geringe Immunogenität 
und einen breiten Zell- und Gewebstropismus aufweisen. Deshalb kann rAAV 
als sicherer Gentherapievektor eingesetzt werden. Zurzeit werden einige 
klinische Studien durchgeführt, die auf dem AAV-Vektor basieren. Das erste 
kommerziell verfügbare Medikament wurde 2012 in Europa zugelassen. 
Eine Limitierung des AAV-Vektors ist jedoch die vergleichbar schlechte 
Transduktionseffizienz. Um Wirtsfaktoren zu identifizieren, die eine Rolle bei 
der AAV2-Transduktion spielen, wurde ein RNAi-Screen durchgeführt.  Die 
Enzyme des SUMOylierungsweges, Sae2 und Ubc9, wurden als 
Restriktionsfaktoren der AAV-Infektion identifiziert. Ähnlich wie die 
Ubiquitinierung, ist die SUMOylierung eine posttranslationale 
Proteinmodifikation, die durch ein E1-aktivierendes Enzym (bestehend aus 
Sae1 und Sae2) und ein E2-konjugierendes Enzym (Ubc9) katalysiert wird. 
Weitere Untersuchungen in dieser Arbeit bestätigen, dass der Knockdown der 
SUMOylierung zu einer höheren AAV-Transduktionsleistung führt, und die 
AAV2-Infektion die gesamte SUMOylierungsaktivität der Wirtszellen erhöhen 
kann. Darüber hinaus beeinflusst die SUMOylierung die Transduktion von 
AAV-Vektoren mit einzelsträngiger DNA (ssAAV) und selbstkomplementärer 
DNA (scAAV). 
Um herauszufinden, was das Zielobjekt der SUMOylierung ist, wurde eine 
Ko-Immunpräzipitation für AAV2-Partikel durchgeführt, welche darauf hindeutet, 
dass das AAV2-Kapsidprotein SUMOyliert wird. Die ortsspezifische 
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Mutagenese und die Transduktion mit dem modifizierten Viruskapsid zeigen, 
dass die Aminosäuren K142/143 und K169 eine Rolle bei der SUMOylierung 
von VP2 spielen. Darüber verhindert die Fusion des N-Terminus mit 
verschiedenen Liganden wie GFP und HA die SUMOylierung von VP2, was 
darauf hindeutet, dass die AAV2-Kapsid-SUMOylierung eine bestimmte VP2 
räumliche Struktur erfordert. 
Darüber hinaus deutet die verstärkte AAV2-Transduktion in der Daxx 
Knockout-Zelllinie, im Vergleich zur wt-Zelllinie darauf hin, dass es sich bei dem 
Daxx-Protein um einen weiteren Restriktionsfaktor der AAV-Infektion handelt. 
Im Vergleich zu Wildtyp-Zelllinien wurden die verstärkenden Effekte nach dem 
Ubc9-Knockdown in der Daxx-Knockout-Zelllinie offensichtlich reduziert, was 
bedeutet, dass das Daxx-Protein und die SUMOylierung auf dem gleichem 
oder sich überlappenden Wegen funktionieren könnten. Ausgehend davon 
könnte nicht nur das AAV2-Kapsidprotein, sondern auch das SUMOylierte 
Daxx-Protein die AAV-Transduktion regulieren. 
Der subzelluläre Transport von AAV2 umfasst mehrere Schritte. Die Menge an 
AAV2-Vektor-DNA in den Zellmembran- und den Zytoplasmafraktionen ändern 
sich nicht nach dem Sae2-Knockdown, was darauf hinweist, dass die 
Beeinträchtigung der SUMOylierung die Bindung von AAV an die Zellmembran, 
den intrazellulären Transport und damit die AAV-Tranduktion nicht beeinflusst. 
Darüber hinaus gibt es zwei Hypothesen für die Akkumulation von 
SUMOylierten AAV2-Partikeln im Zellkern. Die SUMOylierung könnte die 
Anzahl der AAV2 Partikel begrenzen, die den Zellkern erreichen und 
transduzieren können. Im Gegenteil, könnte SUMOylierung die Anzahl von 
AAV2 Partikeln nicht beeinflussen, sondern die AAV Transduktion verbessern, 
indem AAV-uncoating und ssDNA Freisetzung im Zellkern gefördert werden. 
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